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The Epstein-Barr virus (EBV) is a ubiquitous human herpes virus, which infects B-cells. This 
leads to a life-long latent infection, which in most cases is non-pathogenic. However, EBV is 
etiologically associated with several human malignancies, including endemic Burkitt's 
lymphoma, nasopharyngeal carcinoma and post-transplant lymphoma. This association is 
probably linked to the ability of the virus to immortalise B-cells in vitro and to induce B-cell 
proliferation. Mutagenesis of the viral genome has defined a subset of four nuclear proteins 
(EBNA1, 2, 3, and 6) and one membrane protein (LMP1) required for the immortalisation 
process. The aim of the present study was to increase our knowledge about the different 
mechanisms by which the expression of the LMP1 gene is regulated in B-cells focussing on 
the role played by the virally encoded transactivating factor EBNA2. 
The importance of an ATF/CRE site and an Sp site in the proximal part of the LMP1 
regulatory sequence (LRS) was established. Mutations of the ATF/CRE and Sp sites 
decreased both EBNA2-dependent and -independent LMP1 promoter activity in transient 
transfection experiments. Both cAMP and okadaic acid, an inhibitor of protein phosphatase 1 
(PP1) and 2A (PP2A), activated the promoter in an ATF/CRE-dependent fashion. 
Immunoaffinity experiments showed that EBNA2 co-purified with a PPl-like protein from an 
EBV-immortalised B-cell line and that a recombinant EBNA2 fusion protein specifically 
bound and inhibited a PPl-like activity in B-cell extracts. Thus, we conclude that the 
ATF/CRE and Sp site is important in transactivation of the LMP1 promoter and that the 
ability of EBNA2 to block the effect exerted by protein phosphatases on a certain 
transcription factor can be part of the mechanism by which the LMP1 promoter is activated. 
Electrophoretic mobility shift assays showed that both the positive Spl and the negative 
Sp3 transcription factor bound to the Sp site. However, overexpression of the Spl 
transcription factor did not add to the activity induced by EBNA2. The heterodimeric 
transcription factor complexes ATF1/CREB1 and c-Jun/ATF2 bound to the ATF1/CRE site in 
LRS. The binding of ATF1/CREB1 activated the LMP1 promoter in the absence of EBNA2. 
The ATF2 and c-Jun transcription factors, on the other hand, did not activate the LMP1 
promoter in the absence of EBNA2 but did so in the presence of EBNA2. The activating 
effect was abolished if the phosphate-accepting amino acid residues Thr69 and Thr71 in 
ATF2 were mutated. Furthermore, EBNA2 could interact with the c-Jun/ATF2 heterodimer. 
We conclude that EBNA2 is targeted to the promoter by these factors to transactivate the 
LMP1 promoter. 
Histone acetylation at the LMP1 promoter was studied in two different B-cell lines. Both 
EBNA2 and the histone deacetylase inhibitor Trichostatin A (TSA) rapidly increased the level 
of histone acetylation at the LMP1 promoter in resting ER/EB2-5 B-cells. However, only 
EBNA2 induced LMP1 transcription. This was in contrast to the situation in proliferating 
P3HR1 B-cells, in which TSA both increased histone acetylation at and activated transcription 
from the LMP1 promoter. Mutational analysis of LRS showed that the ATF/CRE element was 
an important mediator of the TSA effect. Our results also suggest that both EBNA2 and TSA 
require the presence of phosphorylated ATF2 to activate the LMP1 promoter. 
Keywords: Epstein-Barr virus, B-cell, transformation, LMP1, EBNA2, transcription, 
phosphorylation, histone acetylation. 
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ABSTRACT 
The Epstein-Barr vims (EBV) is a ubiquitous human herpes virus, which infects B-cells. This 
leads to a life-long latent infection, which in most cas es is non-pathogenic. However, EBV is 
etiologically associated with several human malignancies, including endemic Burkitt's 
lymphoma, nasopharyngeal carcinoma and post-transplant lymphoma. This association is 
probably linked to the ability of the virus to immortalise B-cells in vitro and to induce B-cell 
proliferation. Mutagenesis of the viral genom e has defined a subset of four nuclear proteins 
(EBNA1, 2, 3, and 6) and one membrane protein (LMP1) required for the immortalisation 
process. The aim of the present study was to increase our knowledge about the different 
mechanisms by which the expression of the LMP1 gene is regulated in B-cells focussing on 
the role played by the virally encoded transactivating factor EBNA2. 
The importance of an ATF/CRE site and an Sp site in the proximal part o f the LMP1 
regulatory sequence (LRS) was established. Mutations of the ATF/CRE and Sp sites 
decreased both EBNA2-dependent and -independent LMP1 promoter activity in transient 
transfection experiments. Both cAMP and okadaic acid, an inhibitor of protein phosphatase 1 
(PP1) and 2A (PP2A), activated the promoter in an ATF/CRE-dependent fashion. 
Immunoaffinity experiments showed that EBNA2 co-purified with a PP1 -like protein from an 
EBV-immortalised B-cell line and that a recombinant EBNA2 fusion protein specifically 
bound and inhibited a PP1 -like activity in B-cell extracts. Thus, we conclude that the 
ATF/CRE and Sp site is important in transactivation of the LMP1 promoter and that the 
ability of EBNA2 to block the effect exerted by protein phosphatases on a certain 
transcription factor can be part of the mechanism by which the LMP1 promoter is activated. 
Electrophoretic mobility shift assays showed that both the positive Spl and the negative 
Sp3 transcription factor bound to the Sp site. However, overexpression of the Spl 
transcription factor did not add to the activity induced by EBNA2. The heterodimeric 
transcription factor complexes ATF1/CREB1 and c-Jun/ATF2 bound to the ATF1/CRE site in 
LRS. The binding of ATF1/CREB1 activated the LMP1 promoter in the absence of EBNA2. 
The ATF2 and c-Jun transcription factors, on the other hand, did not activate the LMP1 
promoter in the absence of EBNA2 but did so in the presence of EBNA2. The activating 
effect was abolished if the phosphate-accepting amino acid residues Thr69 and Thr71 in 
ATF2 were mutated. Furthermore, EBNA2 could interact with the c-Jun/ATF2 heterodimer. 
We conclude that EBNA2 is targeted to the promoter by these factors to transactivate the 
LMP1 promoter. 
Histone acetylation at the LMP1 promoter was studied in two different B-cell lines. Both 
EBNA2 and the histone deacetylase inhibitor Trichostatin A (TSA) rapidly increased the level 
of histone acetylation at the LMP1 promoter in resting ER/EB2-5 B-cells. However, only 
EBNA2 induced LMP1 transcription. This was in contrast to the situation in proliferating 
P3HR1 B-cells, in which TSA both increased histone acetylation at and activated transcription 
from the LMP1 promoter. Mutational analysis of LRS showed that the ATF/CRE element was 
an important mediator of the TSA effect. Our results also suggest that both EBNA2 and TSA 
require the presence of phosphorylated ATF2 to activate the LMP1 promoter. 
Keywords: Epstein-Barr virus, B-cell, transformation, LMP1, EBNA2, transcription, 
phosphorylation, histone acetylation. 
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INTRODUCTION 
Epstein-Barr virus (EBV) infects over 90 percent of the world's population and persists for 
the lifetime of the infected person. Both primary infection and viral persistence are normally 
asymtomatic. However, an accumulating number of both benign and malignant human 
diseases have been associated with EBV infection. These associations in conjunction with the 
ability of EBV to induce B-cell proliferation and growth transformation explain the interest in 
EBV biology over the past three decades. 
To understand viral pathogenesis it is necessary to unravel the molecular details involved in 
viral infection. Viruses have evolved various strategies to take control over the infected cell 
and direct the cell machinery to produce viral material. During the sometimes millions of 
years of virus and host co-evolution there has been plenty of time to develop complex and 
intimate interactions between the two. Studies on latent and persistent viruses, such as EBV, 
have demonstrated sophisticated strategies to replicate and persist within the host. 
Cells in multicellular organisms are directed by extracellular signals, where different signals 
lead to changes in gene expression and appropriate physiological responses. Viruses have 
evolved numerous genes that function as signal and transcription regulators. In order to 
control the fate of the infected cell, they interfere with cellular functions that regulate cell 
division and growth control. The development of uncontrolled cell growth and malignant 
disease can be one direct consequence of this. 
TRANSCRIPTIONAL REGULATION-AN OVERVIEW 
Transcription and gene expression can be controlled at several different levels including 
transcription initiation, termination of elongation, nuclear RNA processing, mRNA transport 
and mRNA stability. Protein processing, targeting and stability are also important in the 
overall regulation of protein production and subsequent cellular responses. However, 
transcription initiation has turned out to be the major control point in most cases. In the first 
stage of transcription initiation, there is a relief of repression by remodelling of the structure 
of the chromatin at the promoter. In the second stage, a preinitiation complex (PIC) is formed 
7 
at the promoter which contains RNA polymerase II and the general transcription factors 
(GTFs). 
The chromatin template 
Promoter DNA elements 
There are at least three features common to most promoters for protein coding genes. The 
transcription start site or initiation motif (INR), the TATA box and upstream sequences bound 
by transcriptional regulators. The latter sequences have positive (enhancers) and negative 
(silencers) effects. Enhancers and silencers are binding sites for regulatory proteins that can 
act independently of orientation and at long distances from the transcription start site. In 
addition there are elements termed locus control regions (LCR) that consist of complex 
arrangements of multiple regulatory elements. 
Nucleosomes 
The fundamental repeating unit of chromatin is the nucleosome, which is comprised of 146 bp 
of DNA wrapped 1.65 turns around an octamer of histone molecules, two of each H2A, H2B, 
H3 and H4. Nucleosomes are coiled or folded into chromatin fibers. Nucleosomes interact 
with other nucleosomes or additional chromosomal proteins to give this higher-order 
chromatin stucture. Linker histone HI has been implicated in this organisation. Nucleosomes 
repress all genes except those whose transcription is activated by specific positive regulatory 
mechanisms. They repress by occluding sites of protein binding to DNA, thereby interfering 
with the interaction of activators, repressors, basal transcription factors and DNA-modifying 
enzymes. 
Activation and repression 
Gene-specific transcription is stimulated by the binding of activators to enhancers, where they 
recruit and regulate the activities of chromatin modifying complexes and the transcriptional 
apparatus. There is an interplay between activators and repressors and the balance between 
the two determines whether transcription is initiated or not (figure 1). 
Activators 
Activators typically consist of two domains: one that binds specific DNA sequences and one 
that recruits or stimulates the activity of the transcription apparatus. A single activator can 
bind multiple genes, thus providing a mechanism for co-ordinate control of these genes. 
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Individual genes are regulated through the action of multiple activators, thereby providing a 
mechanism for combinatorial control. Multiprotein complexes are formed at enhancers by the 
binding of multiple transcriptional regulators. This arrangement of multiple activators in a 
single complex provides the capacity to integrate multiple regulatory input into a single 
output. Several transcriptional activators, co-activators and general transcription factors have 
been found to possess histone acetylase transferase (HAT) activity (Brown et al. 2000). 
Numerous HATs have now been identified and they are often associated with multiprotein 
complexes. Many DNA-binding transcription factors bind to the co-activators CREB-binding 
protein (CBP) and the closely related p300, which function in co-operation with additional co-
activators (e.g. PCAF) (Vo and Goodman 2001). Both p300 and CBP, but also most of the 
other co-activators, have HAT activity, indicating that multiple HATs are recruited to 
promoters for stimulation of transcription (figure 1). HATs can also acetylate substrates other 
than histones but its role in transcriptional activation is still not fully elucidated. 
Acetylase 
tor 
Mediator complex 
Ac Ac Ac ^Ac RNA polymerase 
and GTFs 
Deacetylase 
Figure 1. Transcription factors bound to promoters can either be activators or repressors. An activator stimulate 
transcription by interactions with co-activators, w hich recruits histone acetylase and direct interactions with the 
Mediator complex. A repressor interacts with co-repressors, which recruits histone deacetylases. 
Repressors 
Gene-specific repressors function by binding to activators or by competing for activator 
binding sites. Many repressors have been found to possess histone deacetylase (HDAC) 
activity (Ng and Bird 2000). HDACs can repress in a gene- or location-specific manner 
through their action on chromatin (figure 1). All known HDACs are found in multiprotein 
complexes. Two mammalian co-repressors, Sin3 and NuRD have been characterised so far. 
Both complexes contain a core of HDAC1 and HDAC2 and the histone binding protein 
RbAP46 and RbAP48. Sin3 was originally identified as a co-repressor for the DNA-binding 
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repressor Mad-Max. However, Sin3 complexes can be recruited by many DNA-binding 
proteins but also by other co-repressors. Deacetylase activity is also linked to repression 
mediated by methylated DNA (Razin 1998). DNA methylation of CpG is involved in 
mammalian gene silencing, where gene-specific methylation correlates inversely with gene 
activity. Furthermore, artificial demethylation results in gene activation. DNA is methylated 
by methyltransferases. The methyl-binding protein MeCP2 bind to HDAC containing 
complexes and form together a very stable repression of promoter activity. 
Chromatin modification 
Covalent modifications of histones 
Possible histon modifications include acetylation, phosphorylation, methylation and 
ubiquitination. Histone acetylation is the best understood of the modifications in terms of 
consequences for transcriptional activity. Several lysines in the N-terminal tail o f each of the 
core histones can be reversibly acetylated. Hyperacetylated histones are associated with 
transcriptionally active DNA regions, wheras hypoacetylated histones are enriched in regions 
that are transcriptionally silent. The discovery that many transcription factors possess HAT 
activity has provided the key evidence for a regulatory role of nucleosomes in transcription. 
The exact mechanisms how histone acetylation facilitates transcription are not known, but it 
may provide access to DNA for the transcription apparatus and its regulators. The other 
covalent modifications of histones are poorly understood. Phosphorylation of the N-terminal 
tail of histone H3 has been linked to increased transcriptional activity. 
Noncovalent modifications of histones 
Nucleosomes are subjected to conformational remodelling in addition to covalent 
modifications. Several remodelling complexes have been identified and the best studied is the 
Swi/Snf complex (Workman and Kingston 1998). All these complexes contain an ATPase 
subunit that is essential for their activity. Remodelling involves the breaking and reforming of 
histone-DNA contacts, although the precise mechanism is unknown. Swi/Snf is likely targeted 
to promoters by DNA-binding transcription activators or the general transcription machinery. 
RNA polymerase II and initiation co-factors 
Transcriptional activators recruit the RNA polymerase II transcription apparatus to promoters 
of protein-coding genes. The apparatus contains the RNA polymerase core enzyme, the 
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general transcription factors (GTFs), and a multisubunit complex called Mediator (Kornberg 
1999). The proposed order of events that lead to transcriptional activation are seen in figure 2. 
Activator UAS 
Co-activator 
URS 
Repressor 
CTD7 TFiiH \ 
J TFIIE 
A TFIIF / TFIID 1 1 TAFs Co-activator Activator 
TBP TFIIB 
UAS 
INR TATA 
Figure 2. Activators recruit co-activators that counteract the action from repressors and co-repressors. GTFs, 
RNA polymerase II and mediator assemble at the promoter initiation site (INR). Concerted interactions between 
transcription factors, co-activators, GTFs and mediator complex then leads to CTD phosphorylation and RNA 
polymerase initiation, elongation and subsequent elevated transcription. 
The RNA polymerase core enzyme 
The RNA polymerase core enzyme has 12 subunits. The largest subunit contains a C-terminal 
domain (CTD) that consists of tandem repeats of a consensus heptapeptide sequence. The 
function of the CTD is closely associated with the phosphorylation status of the domain. RNA 
polymerases found at initiation start sites have dephosphorylated CTDs, while elongating 
polymerases contain heavily phosphorylated CTDs. The switch in CTD phosphorylation 
status appears to cause the RNA polymerase cofactors switch seen in the transition between 
initiation of transcription and elongation, where the preinitiation complex is replaced by the 
factors needed for elongation. 
The general transcription factors 
However, the RNA polymerase requires additional factors for promoter recognition and 
initiation. The GTFs, designated TFIIB, TFIID, TFIIE, TFIIF and TFIIH mediate this. 
Altogether they comprise 23 subunits. The TFIID complex is responsible for promoter 
11 
recognition and contains the TATA-binding protein (TBP) and TBP-associated factors 
(TAFs). They create a context for interaction with TF IIB, which positions the polymerase on 
the promoter. TFIIH contains an ATP-dependent helicase that unwinds the promoter around 
the start site to trigger initiation and a kinase activity capable of phosphorylating CTD. 
Transcriptional activators can bind to GTFs, but these interactions are not sufficient for 
transcriptional activation in a pure in vitro transcription system. Obviously co-activators are 
also needed. 
The mediator complex 
This mediator complex, which contains at least 20 subunits, was originally isolated from the 
yeast Saccharomyces cerevisiae, as an activity needed for transcriptional activation in vitro. 
Later studies have identified Mediator-like complexes also in human cells and demonstrated 
an essential role for the Mediator in the transcription of nearly all RNA pol II dependent 
genes. The Mediator appears responsible for integrating diverse regulatory signals and acting 
as an interface between activators and the RNA polymerase. 
SIGNAL TRANSDUCTION 
To respond to extracellular signals cells have receptor molecules. These fall into two broad 
categories; cell surface receptors and cytoplasmic receptors that act on changes in the 
extracellular environment, respectively. Multiple intracellular signalling pathways then 
mediate the response to modulate the activity of transcription factors, transcriptional 
co-regulators and chromatin-modifying factors, that lead to changes in gene expression 
(figure 3). 
Protein phosphorylation 
Protein phosphorylation is the most frequently used mechanism in signal transduction and 
also the best understood. More than 10% of the proteins in a typical mammalian cell are 
thought to be phosphorylated. Phosphates are transferred from ATP molecules to target 
molecules by protein kinases and are taken off by protein phosphatases. Both protein kinases 
and protein phosphatases are involved in the intricate regulation of cell signalling. Protein 
phosphorylation can regulate distinct transcription factor function by at least five different 
mechanisms (Karin and Hunter 1995; Montminy 1997; Whitmarsh and Davis 2000). 
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(1) Controlling cellular localisation. 
The heterodimeric transcription factor nuclear factor-KB (NF-KB) is regulated by the 
cytoplasmic inhibitor IKB. IKB is phosphorylated in response to signals produced by different 
stimuli. This leads to degradation of IKB and the release and translocation of NF-KB to the 
nucleus. NF-KB binding sites have been identified in a large number of promoters and 
enhancers and include genes involved in immune function, inflammatory response, growth 
control and cell death. Another example is the Notch signalling pathway, which plays an 
important role in cell fate decisions. Activation of the Notch receptor leads to proteolytic 
cleavage of the receptor at the inner side of the cell membrane. The intracellular domain 
(Notch-IC) is then translocated to the nucleus where it activates genes by interacting with the 
Jk recombination signal binding protein (RBP-JK). 
Plasma 
membrane 
Extracellular signal 
Membrane bound 
kinase 
Cytoplasmic _ 
Protein phosphatases 
Nuclear 
membrane 
Nuclear 
Protein phosphatases . 
Cellular response 
1 
Adenylyl cyclase 
Protein kinase 1 
—i 1 
Protein kinase 2 Protein kinase 3 
Nuclear localisation i i 
Transcription factor Protein kinase 3 
1 
R.-P 
Transcription factor 
Figure 3. A schematic figure over possible intracellular signalling pathways in the cell from the plasma 
membrane to the nucleus and transcriptional response. Protein kinases and phosphatases act at all the different 
levels in the signalling cascade. Increase phosphorylation can both lead to activation or repression of 
transcription. 
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(2) Targeting transcription factors for degradation. 
The transcription factors ATF2 and c-Jun are targeted for degradation depending on their 
phosphorylation state. Phosphorylation by the activated c-Jun N-terminal kinase (JNK) or the 
mitogen-activated protein (MAP) p38 kinase protects them from degradation. JNK and p38 
are members of the stress activated protein kinases (SAPK) family and they respond to 
cellular insults or injury and can induce growth arrest. 
(3) Modulating protein-protein interactions. 
Many transcription factors contain phosphorylation-dependent activation domains, and 
sometimes repression domains. The precise mechanisms by which phosphorylation activates 
or represses transcriptional activity are not fully understood. The affinity for co-activators, co-
repressors or basal transcription factors is probably affected. The CREB/ATF and Jun/Fos 
(AP-1) family of transcription factors are among the most studied. The cAMP-response 
element binding protein (CREB) is the prototype transcription factor. Several kinases in 
different signalling pathways can phosphorylate CREB. Phosphorylation of CREB allows the 
recruitment of the co-activator CREB-binding protein (CBP), which is also regulated through 
phosphorylation. This interaction with CBP is proposed to link CREB with components of the 
basal transcription complex in order to activate transcription. 
(4) Regulating DNA binding. 
The DNA binding activity of the transcription factor c-Jun is regulated by both direct and 
indirect phosphorylation. Phosphorylation of c-Jun near the C-terminal DNA bindning 
domain inhibits DNA-binding. Phosphorylation of the N-terminal transactivation domain by 
JNK cause a conformational change in c-Jun, which in turn facilitates dephosphorylation of 
the C-terminal residues and results in increased DNA binding. 
(5) Modifying chromatin structure. 
Remodelling complexes and chromatin modifying enzymes are under signalling dependent 
control. The chromatin remodelling complex Swi/Snf is inactivated by phosphorylation 
during mitosis resulting in a repressive chromatin structure and is activated by 
dephosphorylation when cells exit mitosis. The balance between histone acetyltransferases 
(HATs) and histone deacetylases (HDACs) is controlled by signal transduction pathways. The 
activity of specific HATs is increased or decreased by phosphorylation. 
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THE EPSTEIN-BARR VIRUS 
Classification and genetics 
EBV is a DNA virus and a member of the gamma-herpesvirus family and the prototype virus 
in the lymphocryptovirus subfamily based on its ability to latently infect B-cells. It is the most 
extensively studied virus in this group and the entire genome DNA sequence of the B98-5 
strain of the virus was established already in 1984 employing a library of cloned restriction 
fragments created in Gothenburg (Baer et al. 1984). The virus has a linear double-stranded 
DNA genome of about 172 000 base pairs which encodes approximately 85 proteins, most of 
them involved in viral replication and lytic cycle. A limited set of genes is involved in the 
latent stage of infection. These genes code for six nuclear antigens (EBNA1 to 6), three latent 
membrane proteins (LMP1, 2A and 2B), a complex family of alternative spliced transcripts 
(BARTs) and two small noncoding nuclear RNAs (EBER1 and 2). Reviewed in (Kieff 1996). 
There are two EBV types infecting the human population, formerly designated as types A and 
B, but are now referred to as EBV-1 and EBV-2. There are no clear differences between 
EBV-1 and EBV-2 in terms of efficiency in infecting humans in vivo or in ability to cause 
disease. However, EBV-2 transforms B-cells less efficiently in vitro than does EBV-1 and B-
lymphocytes infected by EBV-2 grow less well in reduced serum concentration and low cell 
density. These differences are primarily determined by differences in the EBNA2 coding gene 
(Cohen et al. 1989). 
Host range and virus propagation 
Humans are the natural host of EBV infection. EBV is an orally transmitted agent and enters 
the host through the oropharynx. Infiltrating B-cells in the epithelium are believed to be the 
prime target. The C3d complement receptor molecule (CD21) is the virus receptor in the 
human host. CD21 expression is largely restricted to mature B-lymphocytes, explaining the 
predominant B-cell tropism of EBV. Glycoproteins in the viral envelope potentiate the 
binding of the virus to the target cell and the fusion of the virus with the host cell membrane. 
Following fusion, viral DNA is released into the cell, becomes circular and is transcribed and 
replicated in the nucleus, where it persists as multiple episomal copies. A co-ordinate 
expression of the latent gene products under the control of the transcription factor EBNA2 
then induces growth transformation and cell proliferation of the infected B-cell. The virus 
then probably uses the normal differentiation pathway of B-lymphocytes to gain access to and 
persist within the long-lived memory B-cell compartment. Usually, EBV remains latent 
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hereafter and viral replication is activated sporadically in a small percentage of the B-cells. 
Several findings suggest that only the B-cell compartment is needed for viral persistence. 
First, patients with X-linked agammaglobulinemia, which lack mature B-cells, are not 
infected by EBV (Faulkner et al. 1999). Second, EBV can be eradicated in bone marrow-
transplant recipients who have received therapy that ablates their hemopoietic cells but not 
their oropharyngeal cells (Gratama et al. 1988). And third, acyclovir treatment abolishes 
shedding of EBV from the oropharynx but does not affect the number of infected B-cells in 
the circulation (Ernberg and Andersson 1986). 
EBV's remarkable success relies on efficient spread from infected to non-infected individuals. 
Virus shedding normally occurs from the oropharynx, with transmission via infectious saliva. 
Memory B-cells normally migrate to mucosal surfaces to fulfil their role in combating 
infection and this is probably how EBV-positive B-cells reach the lymphoepithelium in the 
oropharynx. A controversial question is whether the viral replication takes place in these 
B-cells or in some other cell type in the oropharynx. Since EBV replicates so poorly in 
established B-cell lines in vitro it has been thought that EBV requires an epithelial site of 
replication. EBV infection of epithelial cells in oral hairy leukoplakia (OHL) results in an 
efficient viral replication and release of viral particles (Greenspan et al. 1985). However, 
recent re-examination of the available evidence has questioned whether epithelial cells are 
involved at all in normal EBV infection (Faulkner et al. 2000). Epithelial cells do not 
normally express the CD21 receptor molecule and they are only infected with great difficulty 
in vitro in contrast to the ease and reproducibility by which B-cells can be infected. In situ 
hybridisation techniques have consistently failed to identify infected epithelial cells in normal 
individuals, whereas both latent and replicating EBV can be detected in intra-epithelial 
B-cells (Niedobitek et al. 1992; Karajannis et al. 1997; Niedobitek et al. 1997). 
This means that B-cells but not epithelial cells are essential for persistence and that there is no 
clear evidence for viral replication in epithelial cell in vivo. Thus, it seems reasonable to 
assume that infected B-cells are the sole site of EBV persistence, replication and spread in the 
normal healthy host. However, it should be pointed out that this does not mean that EBV is 
incapable of infecting cell types other then B-cells in vivo. EBV associated diseases of 
epithelial origin, such as nasopharyngeal carcinoma (NPC) and oral hairy leukoplakia (OHL) 
contain both EBV DNA and viral gene products and there is little doubt that EBV plays a role 
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in the pathogenesis of these diseases. But how and when EBV enters these cells is still an 
open question. 
Immune response to EBV infection 
Both a humoral and cellular mediated immunity is seen after EBV infection. Although the 
finding of antibodies directed against viral structural proteins and the EBNAs are important 
for diagnostic use, these antibodies do not seem to protect from new infection or control the 
latent stage of EBV infection. A MHC class I restricted cellular immune response has been 
found to be more important for the control of EBV infection (Rickinson and Moss 1997). 
Primary CD8+ cytotoxic T-cells (CTL) control over-growth of transformed and proliferating 
B-cells during the primary infection, assisted by primary CD4+ T-cells and natural killer 
(NK) cells. Memory CTLs stand for the long-term surveillance of EBV infection. The 
importance of this continued CTL response is evident in situations of T-cell 
immunosuppression (e.g. allograft recipients and AIDS patients) where lymphoproliferative 
disease or EBV positive lymphomas develop with high frequency. Both the primary and 
memory CTL response are markedly skewed toward HLA allele-specific epitopes derived 
from the EBNA3, 4 and 6 subset of latent proteins, with reactivities to other antigens being 
much less frequent. These EBNAs, together with EBNA2, are down-regulated by the virus 
after the initial steps of latent infection and this is probably necessary to escape the host's 
immuno-surveillance and to persist in the memory B-cell compartment. 
Persistence in healthy individuals 
Infected B-cells present several different viral expression patterns depending on stage in 
infection and localisation in the body. Both latent and lytic infection can be detected in tonsils 
from healthy infected individuals. Tonsillar IgD positive naive B-celis express the EBNA2-
dependent lymphoblastoid phenotype, characteristic of primary infection (Joseph et al. 2000). 
Tonsillary germinal center centroblasts and centrocytes as well as memory B-cells are IgD 
negative and express EBNA1 initiated from the Bam Q-promoter (Qp), LMP1 and LMP2 but 
not EBNA2 (Babcock and Thorley-Lawson 2000; Babcock et al. 2000). In the peripheral 
blood, the virus resides latently in resting B-cells that are restricted to the IgD negative 
memory subset (Babcock et al. 1998). These cells however only express LMP2A or no latent 
genes at all (Qu and Rowe 1992; Babcock et al. 2000). EBNAl can only be detected 
sporadically (Chen et al. 1995). The question is how these different expression patterns are 
linked to each other. One possible scenario is that the initial step in infection with expression 
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of the full set of latent gene products is absolutely necessary to efficiently activate the naive 
B-cell and induce a polyclonal differentiation toward a proliferating blast, without appropriate 
antigen stimulation. The activated B-cell blast then switches to a surface IgD negative 
memory B-cell in order to exit the cell cycle. This is normally the only way for a B-cell to 
survive after activation since it can not dedifferentiate back to a naive B-cell. The other option 
is programmed cell death when antigen stimulation becomes limiting. The restricted 
expression seen in the memory B-cells is limited to the viral products that are needed for 
maintenance of the viral episome (EBNA1) and to enhance cell survival (LMP1) or to block 
signals that might activate the viral lytic cycle (LMP2A). A schematic figure over the EBV 
life cycle in vivo, modified from (Babcock et al. 1998; Babcock et al. 2000), is seen in figure 
4, with the proposed stages in infection and possible associated diseases. 
o o 
Primary infection 
Oropharyngeal 
epithelium Lytic phase 
P EBNA1 
Resting 
naive B-cell B-blast Centroblast Centrocyte Memory B-cell 
Immunoblastic Burkitt's Hodgkin's 
lymphoma lymphoma lymphoma Peripheral 
I (without LMPS) I circulation 
Lymph node 
Figure 4. The Epstein-Barr virus life cycle. B-cells are after infection either transformed to proliferating 
lymphoblasts or enters the lytic phase. The infected lymphoblasts mature into IgD negative memory B-cells and 
the expression of latent genes are down-regulated. The viral promoter usage in the different stages is indicated. 
The lytic phase is probably activated in the memory B-cells if and when they enter the oropharynx. The known 
EBV-positive lymphomas and their proposed origin according to their latent gene expression are also shown. 
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EBV-associated diseases 
EBV is associated with an increasing number of both benign and malignant diseases, with 
some of the most studied listed in table 1. All are not discussed in the text. Reviewed in 
(Rickinson and Kieff 1996; Baumforth et al. 1999; Cohen 2000). The ability of EBV to 
induce cell proliferation and transformation is thought to be the main cause, in conjunction 
with specific genetic or environmental factors or immunological changes of the host, for its 
association with disease. 
Infectious mononucleosis 
Whereas most EBV primary infections of infants and children are asymtomatic or only give 
non-specific symptoms, infections of adolescents and adults frequently result in infectious 
mononucleosis (IM). The disease is self-limiting but the convalescence may be very long. The 
reason why some adults get symptoms from the primary infection and others do not, including 
children, is not clear. If IM is an atypical state of infection where the virus infects B-cells 
other than the naive B-cells or simply is an amplified version of the asymtomatic infection 
remains to be determined. 
Lymphoproliferative disease and immunoblastic lymphomas 
The ability of EBV to cause malignant disease is most clearly indicated by the development of 
lymphoproliferative disease and immunoblastic B-cell lymphoma in patients with congenital 
or acquired immunodeficiency. This includes patients with the rare genetic disease X-linked 
lymphoproliferative disease (XLPD), recipients of organ or bone marrow transplants 
undergoing immunosuppressive treatment and patients that have developed AIDS. All these 
patients have impaired T-cell immunity and are unable to control the proliferation of EBV-
infected B-cells. They present symptoms of IM or localised or disseminated 
lymphoproliferation in lymph nodes, liver, lung, kidney, bone marrow, central nervous system 
or the small intestine. XLPD patients often get fatal IM upon primary EBV infection, while 
the minority that survive have a greatly increased risk of developing lymphoma or 
agammaglobulinemia. All allograft transplanted patients have a elevated risk of developing 
post-transplant lymphoproliferative disorder (PTLD), although the incidence varies with the 
organ transplanted and the anti-rejection treatment, from a few percent in bone-marrow 
transplants up to ten to fifteen percent in cardiac transplants. The risk is particularly high after 
the use of the immunosuppressive agent cyclosporine A, which inhibit CTL response. 
Lymphoproliferative disease is a relatively frequent but late manifestation in AIDS patients. 
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AIDS lymphoma often involves the central nervous system, which is a very rare event in 
other forms of immunoblastic lymphoma. Virtually all cases of immunoblastic lymphomas 
are EBV positive with the exception of the AIDS related ones where some 75% to 80% 
appear to be EBV-linked. Immunoblastic lymphomas may be polyclonal, oligoclonal or 
monoclonal at diagnosis. It has been proposed that these lymphomas exhibit an unrestricted 
EBV latent gene expression but there are indications that the heterogeneity within this group 
is more complex with respect to EBV gene expression (Cen et al. 1993). 
Burkitt's lymphoma 
Burkitt's lymphoma (BL) is a high-grade malignant lymphoma of B-cells. T here are three 
different forms recognised, endemic, sporadic and AIDS related. All BL contain a 
chromosomal translocation involving chromosomes 8 and 14, 22 or 2, where t8; 14 is the most 
common. These translocations result in the positioning of the c-myc oncogene near the 
immunoglobulin heavy-chain or light-chain leading to abnormal regulation of c-myc. The 
endemic form shows the strongest and most consistent association with EBV. It is the most 
common childhood tumour in equatorial regions of Africa and Papua New Guinea and at least 
95% of the tumours are EBV positive. It is believed that EBV and malaria infection together 
cause the increase in incidence of endemic BL, where malaria is thought to diminish the 
T-cell control o f proliferating EBV-infected B-cells and thereby increase the probability of 
chromosomal translocations. Tumour tissue samples from these patients usually contain EBV 
gene products, but these are limited to EBNA1 and the non-translated EBV early RNAs 
(EBERs). The EBV genome is monoclonal, indicating that the tumours arise from a single 
EBV-infected cell. They also express high levels of CD10 and CD77, a phenotype resembling 
that of centroblasts in germinal centres of lymph nodes. The other forms of BL hav e a much 
weaker association with EBV infection. The AIDS related BL typically tends to appear earlier 
in the progression toward AIDS than the AIDS related lymphoproliferative and 
immunoblastic lymphoma and before the host immune function is radically impaired. 
Approximately 30% to 40% of the AIDS-BL are EBV positive. In th e sporadic form only 
about 20% of the tumours are EBV positive and the incidence of this type of lymphoma is 50 
to 100-fold less than that of the endemic form. 
Nasopharyngeal carcinoma 
Nasopharyngeal carcinoma (NPC) is an epithelial tumour that, like BL, is characterised by 
marked geographic and population differences in incidence. It is particularly common in the 
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Chinese populations in Southeast Asia, where it accounts for nearly 20% of all malignant 
neoplasm. In contrast to BL, EBV is present in all undifferentiated NPC regardless of 
geographic location or ethnic background of the patient. Just like BL, NPC contains clonal 
EBV episomes suggesting that the tumours arise from a single EBV-infected cell. In s pite of 
this strong association with EBV the aetiology of the disease is poorly understood. The raised 
incidence in specific populations suggests that genetic, cultural or dietary factors rather than 
environmental carcinogens contribute to the development of this disease. NPC patients do not 
have impaired CTL response and the viral gene expression is restricted to EBNA1, EBERs 
and LMP1 and LMP2 expressed independently of EBNA2. 
Hodgkin 's disease 
Epidemiological studies originally suggested a possible role for EBV in the aetiology of 
Hodgkin's disease (HD) with an increased risk of HD following IM. EBV has been detected 
in 40% to 60% of HD cases and EBV genome localises to the malignant component of HD, 
the Reed-Sternberg cells. The viral genomes are monoclonal. The expression pattern has the 
same restriction as NPC. The association of HD with EBV seems to be age-related. HD in 
children and older adults are usually EBV-associated, whereas HD in young adults is less 
frequently EBV-positive. Although the incidence of HD is relatively low this tumour is not 
geographically restricted, making its association with EBV significant in world health terms. 
Table 1. EBV-associated diseases 
Disease Comments EBV genome + (%) Type of latency 
Infectious mononucleosis Primary infection in adolescents. >90 111 
Lymphoproliferative disease and 
Immunoblastic lymphoma 
Immunocompromised patients. 
XLPD, AIDS or post-transplant 
80-100 III 
Burkitt's lymphoma Endemic 
Sporadic 
AIDS 
97 
10-80 
30-40 
I 
Hodgkin's disease Mixed cellularity 
Nodular sclerosing 
Lymphocyte predominant 
>80 
30-40 
<10 
II 
Nasopharyngeal carcinoma Undifferentiated 
see 
100 
40 
II 
T-cell lymphoma Nasal 
Others 
100 
10-40 
II 
Oral hairy leukoplakia Viral replication in tongue epithelium 
of HIV-positive persons. 
100 Mixed lytic and 
latent expression 
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Growth transformation and immortalisation 
Most of our knowledge of the latent stage of EBV infection is based on studies of B-cells 
infection in vitro, lymphoblastoid cell lines and established EBV positive tumour cell lines. 
Considerable efforts have been made to infect and transform other cell types in vitro with 
little or no success. The presence or absence of the CD21 receptor only in part explains these 
difficulties. Cell type specific factors probably determine whether the EBV genome is going 
to be expressed at all after infection, but also if the lytic or latent route is chosen, since EBV 
gene expression is known to be tightly regulated by cellular transcription factors. 
In vitro infection of B-cells with EBV is highly effective and results in the outgrowth of 
infected blasts that can be established as a lymphoblastoid cell line (LCL) with continuos and 
indefinite growth. This transformation and immortalisation is achieved by a seemingly low 
number of viral gene products (table 2) (Kieff 1996). Five of these have been shown to be 
essential (EBNA1, 2, 3, 6 and LMP1) for initiation of B-cell transformation through genetic 
analysis of recombinant viruses. In addition, EBNA5 has been shown to significantly improve 
the outgrowth of transformed cells. EBNA1, EBNA2 and LMP1 are also required for 
maintenance of transformation. One should however bear in mind that functional redundancy 
among the non-essential genes might permit the deletion of one but not several genes 
simultaneously. EBV display several distinct gene expression programmes, according to the 
host cell. At least three different latency programmes can be seen in established tumour cell 
lines and LCL, all of which are distinct from the lytic cycle. They are referred to as latency J, 
II and III (Rickinson and Kieff 1996). 
Latency III 
The best-characterised latency programme is latency III, or growth program of latency, found 
in LCLs after infection of B-cells in vitro. These cells are probably equivalent to those 
produced in vivo upon initial infection but are also seen in a number of EBV associated 
diseases; infectious mononucleosis, X-linked lymphoproliferative disease, post-transplant and 
AIDS related lymphoproliferative disease and immunoblastic lymphoma. All the latent gene 
products are expressed in this latency. The EBNA2 transactivated Bam C-promoter (Cp) is 
used to express the EBNAs. Expressions of the LMPs are EBNA2 dependent. 
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Latency I 
This latency is found in EBV positive Burkitt's lymphoma and is restricted to expression of 
the EBNA1 protein, a complex of transcripts from Bam HI A (BARTs) and non-translated 
small RNAs (EBERs). EBNA1 expression is initiated from the Bam Q-promoter (Qp). This 
latency resembles to some extent the resting state in which infected memory B-cells escape 
the immune response. 
Latency II 
This latency is found in Hodgkin's disease (HD), T-cell lymphomas and nasopharyngeal 
carcinoma (NPC). The viral expression is limited to EBNA1 expressed from the Qp, LMPs, 
EBERs and BARTs. The expressions of the LMPs are EBNA2 independent. 
Functions of the EBV latent gene products 
EBNA5 
EBNA5, also called EBNA-LP, is together with EBNA2 the first viral g enes expressed after 
primary infection of B-cells. EBNA5 is not absolutely necessary for EBV mediated B-cell 
transformation but greatly enhances the efficiency of the process (Mannick et al. 1991). 
EBNA5 can interact with the cell cycle regulators and tumour suppressor gene products p53 
and Rb in vitro (Szekely et al. 1993) but there is no evidence that their functions are modified 
by EBNA5 in vivo (Allday et al. 1995; Inman and Farrell 1995). EBNA5 is involved in 
transcriptional regulation but the precise mechanism by which this is achieved is not clear. 
EBNA5 stimulates the EBNA2 activation of the LMP1 promoter in several different assays, 
but also the LMP2 and the C-promoter (Harada and Kieff 1997; Nitsche et al. 1997). This 
EBNA5 dependent co-stimulation might be mediated through the CBFl/RBP-Jk binding site 
(Harada and Kieff 1997). EBNA5 has also been implicated in transcriptional repression. The 
effect might be mediated through inhibition of pre-mRNA cleavage and polyadenylation 
(Dufva et al. unpublished investigation). 
EBNA2 
The essential role of EBNA2 in growth transformation was first evident in studies of the EBV 
infected BL line, P3HR1. The P3HR1 virus was found to be non-transforming because of a 
deletion that removed all th e EBNA2 coding regions and the last two exons of EBNA5. The 
transforming ability could only be retained by EBNA2 (Cohen et al. 1989; Hammerschmidt 
and Sugden 1989). This means that EBNA2 is required for initiation of B-cell transformation 
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but EBNA2 is also essential for maintenance of transformation (Kempkes et al. 1995c). 
EBNA2 is the major determinant of the differences between EBV-1 a nd EBV-2 in ability to 
induce transformation (Cohen et al. 1989). The EBV-1 (B95-8 strain) EBNA2 consists of 487 
amino acids whereas the EBV-2 (AG876 strain) EBNA2 consists of 443 amino acids. 
Sequence comparison between the closely related baboon herpes virus papio (HVP), EBV-1 
and EBV-2 has identified eight conserved regions in the EBNA2 coding gene (Ling et al. 
1993b) (figure 5). EBNA2 is a phosphoprotein phosphorylated on serines and threonines. The 
EBNA2 C-terminus is a substrate for casein kinase 2 in vitro (Grässer et al. 1992). 
EBNA2 is one of the first viral gene s expressed after infection and EBNA2 coordinates the 
cascade of events leading to B-cell growth transformation. EBNA2 is a specific 
transcriptional activator of both viral and cellular genes. The Bam W promoter (Wp) is 
initially used to express the EBNAs during B-cell transformation. This promoter is not 
dependent on viral gene products for its activation. However, shortly after infection the 
promoter usage is switched from the Wp to the Cp promoter by EBNA2 (Woisetschlaeger et 
al. 1991). Cp is then regulated by EBNA2 (Sung et al. 1991; Jin and Speck 1992). EBNA2 
also upregulates the LMP1 (Abbot et al. 1990; Wang et al. 1990b) and the LMP2 promoters 
(Zimber-Strobl et al. 1991). In additio n, several cellular genes are up-regulated by EBNA2, 
including the B-cell activation marker CD23 (Wang et al. 1987), the complement and EBV 
receptor CD21 (Cordier et al. 1990) and the proto-oncogenes c-fgr (Knutson 1990) and c-myc 
(Kaiser et al. 1999). EBNA2 also down-regulate the expression of the immunoglobulin heavy-
chain locus (Ig|i) gene (Jochner et al. 1996). EBNA2 is involved in cell cycle regulation. 
Growth arrest occurs at Gi and G2 stages o f the cell cycle when EBNA2 is withdrawn in B-
cells conditional for EBNA2 function (Kempkes et al. 1995c). EBNA2 and EBNA5 can c o­
operate to cause Go to G i transition in the cell cycl e during the transformation of resting B-
cells (Sinclair et al. 1994). This is probably achieved by up-regulation of cyclin D2 
expression. However, this induction is a secondary event, which require de novo protein 
synthesis (Kaiser et al. 1999). S phase entry from Gi can also be regulated by EBNA2 since 
the proto-oncogen c-myc facilitates G] to S transition and the c-myc gene is a direct target for 
EBNA2 activation (Kaiser et al. 1999). 
24 
5jO 1P0 1^0 2p0 250 3P0 3?0 4p0 4$0 
D-
1 
I I I EBNA2 
poly-proline 
• 
i j 
Arg-Lys 
repeat 
acidic domain 
-D-D • •—Q 
i i 
Conserved regions 
(EBV-1, EBV-2 and HPV) 
B-cell transformation 
LMP1 transactivation 
C promoter transactivation 
Activation domain 
(TFIIB, TFIIH, TAF40, RPA70, p300, CBP) 
Promoter targeting 
(RBP-Jk, PU.1) 
Chromatin remodelling 
(Swi/Snf) 
Self association 
PP1 interaction and inhibition 
Figure 5. Functional domains in the EBNA2 protein. 
Deletion analysis and directed mutagenesis of EBNA2 have identified essential regions for 
B-cell transformation in vitro (Cohen et al. 1991) and transactivation of the Cp and LMP1 
promoters (Cohen and Kieff 1991; Sjöblom et al. 1995b) (figure 5). The EBNA2 C-terminal 
domain (aa. 426-462) is required for both B-cell transformation and for transactivation. A 
core motif in this domain (aa. 449-462) can be substituted by the VP 16 acidic activation 
domain (Cohen and Kieff 1991 ; Cohen 1992). This F.BNA2 domain has been found to interact 
with components of the RNA polymerase II transcription machinery. These are TFIIB, 
TAF40, TFIIH, RPA70 and indirectly TFIIE via a protein called plOO (a et al. 1995; Tong et 
al. 1995b; Tong et al. 1995c; Wu et al. 1996). The acidic domain of EBNA2 also interacts 
directly with the transcriptional co-activators CBP and p300 and indirectly with PCAF 
(Jayachandra et al. 1999; Wang et al. 2000), indicating that EBNA2 can recruit both basal 
transcription factors and histone acetylase transferases (HATs) to activate transcription. 
EBNA2 can also interact with the chromatin modulating human Swi/Snf complex and target it 
to promoters through binding with the hSNF5/Inil subunit (Wu et al. 1996; Wu et al. 2000). 
This interaction involves amino acids 1-170 and 182-344 in E BNA2 (figure 5). The targeting 
seems to be dependent on presence of RBP-Jk binding sites in the promoter (Wu et al. 2000). 
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EBNA2 lacks sequence specific DNA-binding ability and the participation of cellular DNA 
binding proteins is necessary for targeting of EBNA2 to specific promoters. The region 
between amino acid 280 to 337 in EBNA2, also required for B-cell transformation and 
transactivation, seems to mediate promoter targeting of EBNA2. This part of EBNA2 
interacts with the DNA-binding protein Jk recombination signal binding protein (RBP-JK) 
(Ling et al. 1993a; Grossman et al. 1994; Henkel et al. 1994; Waltzer et al. 1994; Zimber-
Strobl et al. 1994), also referred to as Cp-binding factor 1 (CBF1). Amino acids 310 to 336 of 
EBNA2 are sufficient for this interaction and a short conserved motif, PPWWPP (aa. 317-
322), probably mediates the interaction (Yalamanchili et al. 1994). The RBP-JK DNA-binding 
site was originally identified by virtue of its ability to confer EBNA2 inducibility to the Cp, 
CD23 and LMP2A promoters (Zimber-Strobl et al. 1993; Ling et al. 1994) but most EBNA2 
responsive promoters, including the LMP1 promoter, seem to contain one or more RBP-JK 
sites. RBP-JK is a transcriptional repressor. The repression on promoter activity is probably 
mediated by interaction with the RBP-JK binding protein SKIP and recruitment of a co-
repressor complex containing C1R, SMRT, Sin3A, SAP30 and the histone deacetylases 
HDAC1 and HDAC2 (Hsieh et al. 1999; Zhou et al. 2000). The current model for EBNA2 
transactivation through the RBP-JK site is that EBNA2 both binds to RBP-JK a nd SKIP to 
replace this co-repressor complex (Hsieh and H ayward 1995; Zhou et al. 2000). The RBP-JK 
protein is expressed ubiquitously and has been highly conserved throughout evolution. 
Mutation of the RBP-JK gene results in embryonic lethality in such diverse species as mouse 
and fruit fly. RBP-JK is a component in the Notch signalling pathway and binds to the 
intracellular domain of the receptor Notch (Notch-IC). Ligand mediated activation of Notch 
results in cleavage and release of its intracellular domain, which translocate to the nucleus and 
indirectly binds to DNA through its interaction with RBP-JK. Thus, EBNA2 seems to mimic 
activated Notch. Accordingly, Notch-IC can substitute for EBNA2 in transactivation of 
cellular and viral promoters to some extent (Höfelmayr et al. 1999; Strobl et al. 2000) and 
Notch-IC can partially replace EBNA2 function in B-cell immortalisation and maintenance of 
B-cell proliferation (Gordadze et al. 2001; Höfelmayr et al. 2001). However, it i s interesting 
to note that Notch-IC was unable to or could only with great difficulty induce LMP1 
expression in these experiments. 
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Regarding the LMP1 promoter, a PU box motif and an adjacent octamer motif in the enhancer 
region have been shown to be just as or more important than the RBP-Jk site in EBNA2 
transactivation. The Ets-related PU.l/Spi-1 and Spi-B transcription factors and an unidentified 
POU-domain transcription factor bind these motifs respectively (Laux et al. 1994a; Johannsen 
et al. 1995; Sjöblom et al. 1995a; Sjöblom et al. 1995b). The Ets family of transcription 
factors regulate a wide variety of cellular genes and are important for B-cell development and 
differentiation. The same EBNA2 domain responsible for RBP-Jk binding might be involved 
in binding to the PU.l transcription factor and subsequent targeting to the LMP1 promoter 
(Johannsen et al. 1995). However, there are data suggesting that the EBNA2 PU.l interaction 
is indirect, probably mediated by the POU-domain binding protein (Sjöblom et al. 1995a). 
There appears to be a requirement for several EBNA2 molecules to enable all the interactions 
with co-activators and transcription factors that are necessary for appropriate promoter 
regulation. Several lines of evidence are consistent with the possibility that EBNA2 is present 
in a multimeric form in vivo (Grässer et al. 1991; Tsui and Schubach 1994) and that this is an 
important feature for transactivation and transformation. Essential parts of EBNA2 have also 
been shown to be involved in self association (aa.1-60, 96-210 and 232-344) (Tsui and 
Schubach 1994; Harada et al. 2001). 
EBNA3, 4 and 6 
The EBNA3, 4 and 6 proteins are encoded by genes adjacent to each other in the EBV 
genome and are in an alternative nomenclature also called EBNA3A, 3B and 3C respectively. 
EBNA3 and EBNA6 are essential for growth transformation whereas EBNA4 is not 
(Tomkinson et al. 1993). EBNA3 is dispensable in maintenance of transformation (Kempkes 
et al. 1995b). Information on the role of EBNA6 in maintenance of transformation is not 
available. EBNA3 and EBNA6 have been shown to participate in transcriptional regulation of 
LMP1 (Wang et al. 1990a; Allday et al. 1993) and all three EBNAs bind the transcription 
factor RBP-Jk and inhibit transcriptional activation of EBNA2-responsive promoters (Le 
Roux et al. 1994; Radkov et al. 1997) by preventing EBNA2- RBP-Jk complexes from 
binding to their cognate RBP-Jk binding sites (Robertson et al. 1996; Waltzer et al. 1996). 
EBNA6 also interacts with a histone deacetylase (HDAC1), indicating that the repression of 
transcription could be mediated through histone deacetylation (Radkov et al. 1999). One 
function of the EBNA3, 4 and 6 proteins may thus be to counterbalance and fine-tune the 
action of EBNA2 on different promoters. 
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EBNAl 
The EBNAl protein is involved in viral replication and is essential for maintenance of the 
EBV episome (Yates et al. 1985). EBNAl is expressed in all established EBV positive cell 
lines and most EBV positive cells in vivo. EBNAl is a phosphoprotein and binds DNA as a 
dimer co-operatively to two groups of binding sites within the origin of replication, oriP, in 
the EBV genome. The main role of EBNAl/or/P may be to ensure stability of the replicated 
DNA and segregation into the daughter cells at cell division (Mackey and Sugden 1999). 
EBNAl is also an activator of EBNA transcription via oriP. The EBNAl protein contains a 
large domain of 239 amino acids with a repeated sequence of glycine-glycine-alanine. This 
domain has been shown to be important during the latent phase in vivo. The repeat domain 
efficiently inhibits the ubiqutin/proteasome-dependent degradation of EBNAl and thereby 
prevents presentation of EBNAl epitopes on MHC class I molecules (Levitskaya et al. 1995). 
This could explain why EBV infected cells in which viral antigen expression is limited to 
EBNAl can escape the hosts immune surveillance mediated by CTLs. Evidence that EBNAl 
itself has oncogenic potential is provided by the finding that B-cell lymphomas developed in 
transgenic mouse lines expressing EBNAl under the control of the immunoglobulin heavy-
chain intron enhancer (Wilson et al. 1996). However, this finding has not been further verified 
and it is still a controversial issue whether EBNAl is an oncogene or not. 
LMP2A and 2B 
The LMP2 gene encodes two distinct proteins, LMP2A and LMP2B, which are produced 
through alternative splicing. Neither is required for B-cell transformation (Longnecker et al. 
1992; Speck et al. 1999). They are integral membrane proteins and LMP2A is a substrate for 
src family tyrosine kinases. LMP2B lacks the amino-terminus, which contains the kinase 
interacting domain. LMP2A seems to block the signal transduction through the B-cell antigen 
receptor complex (BCR) (Fruehling and Longnecker 1997). This may inhibit reactivation of 
the virus from the latent state to the lytic cycle. The function of LMP2B is unclear but it may 
form complex with and modulate LMP2A function. 
LMP1 
Genetic studies have revealed that LMP1 is essential for transformation of B-cell in vitro and 
its continuous expression is required for maintenance of LCL growth (Kaye et al. 1993). 
However, LMP1 alone is not sufficient to sustain B-cell proliferation (Zimber-Strobl et al. 
1996). LMP1 is unique among the latent gene products expressed during the immortalisation 
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process in that it alone induces the classic phenotypic changes associated with EBV 
transformation in rodent fibroblasts and these cells are tumourigenic in nude mice (Wang et 
al. 1985). Thus, LMP1 is an oncogene. Transgenic mice with the LMP1 gene under the 
control of the Ig heavy chain promoter develop lymphomas (Kulwichit et al. 1998). It sha res 
multiple features with the tumour necrosis factor receptor 1 (TNFR1) molecule (Mosialos et 
al. 1995) and the CD40 molecule (Gires et al. 1997), although they differ strikingly in 
structure. LMP1 can partially restore the CD40 phenotype in CD40 deficient mice (Uchida et 
al. 1999) and LMP1 can activate the same signalling pathways as these molecules. However, 
LMP1 has additional functions absent from the CD40 and TNFR1 molecules (Farrell 1998; 
Kieser et al. 1999; Kaykas and Sugden 2000). 
LMP1 is an integral membrane protein with six transmembrane domains with both the N- and 
C-terminus at the cytoplasmic side of the cell membrane. LMP1 is phosphorylated on serin 
and threonine residues and has a short half-life of approximately 2 hours in the plasma 
membrane (Baichwal and Sugden 1987; Mann and Thorley-Lawson 1987). LMP1 is highly 
toxic if expressed at high levels (Hammerschmidt et al. 1989). LMP1 aggregates in the 
plasma membrane with members in the TNFR family and binds to TNFR associated factors 
(TRAFs) (Devergne et al. 1996), TNF associated death domain protein (TRADD) (Izumi and 
Kieff 1997) and Janus kinase 3 (JAK3) (Gires et al. 1999). No extracellular ligand has been 
identified and LMP1 behaves as a ligand-independent and constitutively active signalling 
molecule. LMP1 has at least three domains important for its functions, referred to as 
C-terminal activating regions (CTAR), CTAR1 (aa. 186-231), CTAR2 (aa. 351-386) and 
CTAR3 (aa. 275-280 and 302-307). 
At least four signalling pathways are implicated in the function of LMP1 (figure 6). (1) 
Activation of the transcription factor NF-kB, through CTAR1 and CTAR2 independent of 
each other (Huen et al. 1995). (2) Activation of the c-Jun N-terminal kinase (JNK) pathway, 
also known as the stress activated protein kinase (SAPK) pathway, through CTAR2, which 
leads to transcription factor AP-1 activation (Kieser et al. 1997; Eliopoulos et al. 1999a). (3) 
Activation of the mitogen activated protein kinase (MAPK) p38 through CTAR1 and CTAR2 
independent of NF-kB activation, which leads to transcription factor ATF2 activation. 
(Eliopoulos et al. 1999b). (4) Activation of the JAK3 kinase in the JAK/STAT (signal 
transducers and activators of transcription) pathway, through CTAR3, which leads to 
activation of transcription factor STAT1 and STAT3. 
29 
LMP1 
Plasma 
membrane 
TRAF1,2,3 CTAR1 
IKK? JAK3 
CTAR3 
JAK3 
TRÄDD CTAR2 
1KB Y NF-KB i38/MAPKj) TRAF2 
JNK/SAPK 
STAT1,3 AP-1 NF-kB 
I I I  I  
Transcriptional regulation 
Figure 6. Signalling pathways involved in LMPl functions. Both NF-KB and p38/MAPK signalling are 
mediated through CTAR1 and CTAR2 domains via TRAF molecules. JNK/AP1 signalling is mediated through 
CTAR2 via TRAF and JAK/STAT signalling is mediated t hrough the recently identified CTAR3 domain. The 
net result of theses signals regulate transcription of various cellular genes and is responsible for many of the 
pleitropic effects of LMPl. Modified from (Baumforth et al. 1999). 
LMPl up-regulate several cellular genes that are associated with either EBV infection or 
antigen activation of primary B-cells. Among them are cell surface markers such as CD23, 
CD39, CD40, CD44 and MHC class II and cell a dhesion molecules such as ICAM-1, LFA1 
and LFA3 (Wang et al. 1988). LMPl also induces cytokines with autocrine growth factor 
activity such as IL-6 and IL-8 (Eliopoulos et al. 1999b). LMPl has also been shown to protect 
infected B-cells from programmed cell d eath or apoptosis. This effect is partly mediated by 
induction of the antiapoptotic cellular proteins Bcl-2 and A20 (Gregory et al. 1991; 
Henderson et al. 1991 ; Laherty et al. 1992). 
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Table 2. Functions of the EBV latent gene products. 
B-cell Expressed 
Viral gerie/protein Properties transformation in latency 
EBNAl Essential for B-cell transformation. Required for viral 
replication/maintenance. Activates EBNA transcription via 
oriP (Cp/Wp). 
+ I-III 
EBNA2 Essential for B-cell transformation. Transcriptional activation 
of EBNA (Cp), LMP1, LMP2B and cellular genes. Associates 
with sequence-specific DNA-binding factors such as RBP-Jk 
and PU.l 
+ III 
EBNA3/EBNA3A Essential for B-cell transformation. Transcriptional repression 
of LMP-1 and LMP-2B. Binds RBP-Jk and antagonizes 
EBNA2/RBP-Jk function. 
+ III 
EBNA4/EBNA3B Not essential for B-cell transformation. Transcriptional 
repression of LMP1 and LMP2B. Binds RBP-Jk and 
antagonizes EBNA2/RBP-Jk function. 
-
III 
EBNA6/EBNA3C Essential for B-cell transformation. Transcriptional repression 
ofLMPl and LMP2B. Activator of LMP1 and cellular genes. 
Binds RBP-Jk and antagonizes EBNA2/RBP-Jk function. 
+ 111 
EBNA5/EBNA-LP Not essential, but enhances efficiency of B-cell transformation. 
Potentiator of transactivation by EBNA2. Cooperates with 
EBNA2 during primary infection of resting B cells to induce 
the Go to Gi transition. 
+/- III 
LMP1 Essential for B-cell transformation. Oncogenic potential. Can 
regulate cell growth, but its main functions is to enhance cell 
survival. Alters cell phenotype. 
+ II-III 
LMP2A/TP1 Not essential for B-cell transformation. Affects BCR signalling 
to inhibit reactivation of virus. Substrate forsrc family 
tyrosine kinases. 
-
II-III 
LMP2B/TP2 Not essential for B-cell transformation. LMP2B is an 
alternatively spliced gene product that is identical to LMP2A 
except that it lacks the amino-terminus kinase-interacting 
domain. Its function is unclear, but it may complex with and 
modulate LMP2A function. 
II-III 
EBER1&2 Not essential for B-cell transformation. Small nuclear RNAs; 
bind autoantigen La, dsRNA-dependent protein kinase and 
ribosomal protein L22. Regulation of translation (?). 
-
I-III 
BARTs Not essential for B-cell transformation. Complex spliced 
transcripts, may encode at least two polypeptides (RK-BARFO 
and RPMS1). Function unknown 
-
l-lll 
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Regulation of the LMP1 gene promoter 
LMP1 can be expressed in many different cellular environments and its expression is 
influenced by both cellular and viral factors. The regulation of the LMP1 gene has been 
investigated in both B-cells and epithelial cells and several factors important in the regulation 
have been identified. However, the precise mechanism used by the virus to modulate the 
expression in different situations is still not fully understood. 
Methylation at the LMP1 promoter 
DNA methylation has been implicated in regulation of promoter usage in EBV. Methylation 
of the EBV genome varies depending on the form of latency and the genome is almost 
unmethylated in LCLs with the unrestricted expression of latent gene products. Conversely, 
the EBV genome in BL and NPC is highly methylated. The role for DNA methylation in 
LMP1 regulation has been addressed in some studies. Treatment with the nucleotide analogue 
5-Azacytidine results in demethylation in the BL-cell line Rael, which normally only 
expresses EBNA1. This results in expression of all the EBNAs and the LMP1 protein 
(Masucci et al. 1989). There are also a correlation between unmethylated DNA at the LMP1 
promoter and expression of LMP1 in NPC biopsies, in est ablished BL cell lines and LCLs 
(Ernberg et al. 1989; Hu et al. 1991; Falk et al. 1998). 
Expression in different cell types 
EBNA2 is required for LMP1 expression in B-cell li nes and during in vitro transformation of 
B-cells (Abbot et al. 1990; Få hraeus et al. 1990; Wang et al. 1990b). LMP1 can unde r certain 
circumstances be expressed independently of EBNA2 in B-cells (Cordier-Bussat et al. 1993) 
and LMP1 is not always expressed in EBNA2 positive B-cells (Cordier et al. 1990) 
underscoring the complex nature of LMP1 regulation. EBNA2 dependent LMP1 expression is 
seen in vivo during the initial stages of primary B-cell infection in the normal hosts. However, 
this requirement for EBNA2 is lifted in the later stages of EBV driven B-cell differentiation 
towards the persistent stage in the memory B-cell compartment (Babcock et al. 1998; 
Babcock et al. 2000). 
LMP1 expression in epithelial cell lines is independent of EBNA2 (Fâhraeus et al. 1988; 
Young et al. 1988) and EBNA2 expression is not seen in LMP1 positive epithelial cells 
(NPC), in T-cells (T-cell lymphomas) or in Reed-Sternberg cells (Hodgkin's), where a latency 
II exp ression is present, underlining that cellular or viral factors can substitute for EBNA2 
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functions in these cells. Epithelial cells are also unresponsive to EBNA2 transactivation of the 
LMP1 gene, as determined by EBNA2 co-transfection with LRS reporter constructs (Fåhraeus 
et al. 1993), indicating that these cells lack some important cellular factor needed in EBNA2-
dependent activation. 
Promoter usage 
The LMP1 gene can be expressed from several different promoters. During the latent phase of 
infection the ED-LI promoter (EcoRI D leftward promoter 1) is primary used in B-cells 
(Farrell et al. 1983; Fennewald et al. 1984). During the lytic phase the ED-L1A promoter is 
used instead, which gives rise to a truncated version of LMP1 (Hudson et al. 1985). A few 
other promoters have also been identified, but these are less active in B-cells and seem to be 
involved in LMP1 expression in epithelial cells, although it is not ruled out that they can be 
important in B-cells during some stage of infection. Previous investigations and the present 
work have been focused on the regulation of the ED-LI promoter in B-cells. 
Regulatory elements 
A sequence spanning from +40 to -634 relative to the ED-LI promoter initiation site has been 
defined as the LMP1 transcription regulatory sequence (LRS) (Fåhraeus et al. 1990). Studies 
on LRS in B-cells have established that there is a complex set of both negative and positive 
cis-acting regulatory elements involved in LMP1 regulation. The region between position -54 
and +40 contains a positive transcription element that is constitutively active. The -106 to 
+40 and -176 to -136 region contribute to EBNA2 responsiveness independently of each 
other (Fåhraeus et al. 1990; Fåhraeus et al. 1993; Sjöblom et al. 1995a) as well as the region 
between -234 to -205 (Ghosh and Kieff 1990; Tsang et al. 1991). These regions contain 
negative regulatory elements that prevent adjacent positive elements from functioning in 
B-cell. This negative effect must be overridden in order to activate transcription. 
Subsequent investigations have identified several of the regulatory elements and the factors 
binding to them (figure 7). Two sites for the EBNA2 binding factor RBP-Jk have been 
identified in LRS, where only the more proximal element has been implicated in 
transcriptional activation (position -223 to -213) (Laux et al. 1994a; Laux et al. 1994b; 
Johannsen et al. 1995). However, its role in EBNA2 activation of LMP1 is complex. Reporter 
constructs lacking the RBP- JK site can still be activated by EBNA2 (Fåhraeus et al. 1990; 
Fåhraeus et al. 1993; Johannsen et al. 1995; Sjöblom et al. 1995a; Sjöblom et al. 1995b) and a 
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reporter construct containing four tandem RBP-JK sites is not EBNA2 responsive (Ling et al. 
1993a). Furthermore, activated Notch, which is able to activate other RBP-Jk site containing 
promoters, can not replace EBNA2 in LMP1 activation (Gordadze et al. 2001; Höfelmayr et 
al. 2001). Two elements in the promoter downstream of RBP- JK seem to be more important 
for EBNA2 transactivation, an octamer motif (position -147 to -139), where a POU-domain 
protein binds (Sjöblom et al. 1995a), and a PU-box (position -171 to -155), where PU.l/Spi-1 
and Spi-B bind (Laux et al. 1994a; Johannsen et al. 1995; Sjöblom et al. 1995a; Sjöblom et al. 
1995b). These two elements seem to cooperate to generate EBNA2 responsiveness, possibly 
through interactions between each other and EBNA2 (Sjöblom et al. 1995a). Additional 
activating elements in the distal part of LRS do not seem to contribute to EBNA2 
responsiveness but might still be important in EBNA2 independent transactivation of the 
LMP1 gene (Johannsen et al. 1995; Sjöblom et al. 1995a; Sjöblom et al. 1995b). The nature of 
the observed EBNA2 response in the proximal part of LRS (-106 to +40) (Sjöblom et al. 
1995a) and the contribution from these elements in LMP1 regulation has not been 
investigated previously. This is the subject for this thesis. 
RBP-JK PU-box ATF/CRE 
Octamer E-box 
+40 
-200 -150, -100 +634 -300 -250 
m i i i i i n 
ISRE I LBF2,3,5,6,7\ SIE 
AML1 LBF4 
Figure 7. A schematic representation of the LMP1 gene regulatory sequence (LRS) in the B95-8 EBV strain 
genome. The RBP-JK, oct amer motif, PU-box, E-box, ATF/CRE and Sp sites are discussed i n the text. T he 
ISRE, AM L1, SIE and LBF2-7 sites have been identified as protein binding elements but are not believed to 
participate in EBNA2 response and are not discussed in the text. 
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THE PRESENT INVESTIGATION 
The aim of the present investigation was to increase our knowledge about the mechanisms by 
which the LMP1 gene is regulated in B-cells and the roles of the EBNA2 transcription factor 
in particular. 
Paper I 
The region near the transcription initiation site in the LMP1 transcription regulatory sequence 
(LRS) (Fåhraeus et al. 1990) contains a putative TATA-box and an activating transcription 
factor or cAMP responsive element (ATF/CRE) (Ghosh and Kieff 1990). Between these two 
cis-acting elements was a GC-rich sequence observed matching the consensus motif for the 
binding site of the ubiquitous transcription factor Spl. The aim of our investigation was to 
reveal the significance of these two elements and the possible involvement of cAMP in the 
regulation of the LMP1 promoter. 
A 5'-deletion and mutational analyses of the LRS promoter proximal region linked to the 
CAT reporter gene was performed. The analyses of the ATF/CRE-site in three different LRS 
constructs (pgLRS-55CAT, pgLRS-259CAT and pgLRS-634CAT) showed that the 
ATF/CRE-site was important for both EBNA2 dependent and EBNA2 independent activation 
of the LMP1 promoter in transient transfection experiments in the EBV negative B-cell line 
DG75. In addition, co-transfection of LRS constructs with a plasmid encoding the CREB 
antagonist CREMß caused a significant reduction of LRS-CAT activity, demonstrating that a 
factor described to bind specifically to ATF/CRE affects LRS promoter activity. On the other 
hand the deletion analysis including the Sp site (pgLRS(-41)CAT) in the reporter construct 
did not show any detectable activity and co-transfection of the constitutively active 
pgLRS(-54)CAT (Fåhraeus et al. 1990; Fâhraeus et al. 1993) with an Spl expression vector 
into the Spl-negative Schneider cells did not change the activity of the construct. As these 
result did not support a significant role for the Sp factors in LMP1 regulation our investigation 
was focused on the ATF/CRE site. 
In line with the assumption that LRS contains a functional cAMP responsive element, cAMP 
was demonstrated to activate the promoter in the absence of EBNA2 in t ransient transfections 
in DG75 cells. This effect was dependent on an intact ATF/CRE. cAMP could also increase 
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LMP1 protein expression in the EBV positive cell lines Cherry and B95-8. However, cAMP 
treatment of the EBV positive but EBNA2-deficient B-cell line P3HR1 did not stimulate 
expression of LMP1, indicating that differences in the cellular context influence the ability for 
LMP1 to be induced by cAMP. In these experiments we also saw that cAMP markedly 
inhibited DG75 cell proliferation, although it d id not kill the cells as determinded by trypan 
blue exclusion. This was not observed in the Cherry or B95-8 cell lines. Interestingly, DG75 
cells stably transfected with an LMP1 expression vector were protected from the inhibitory 
effect of cAMP on cell proliferation. 
It is known that serine/threonin protein phosphateses play an important role in the cAMP 
signalling pathway and that transcription factors binding to ATF/CRE are phosphoproteins, 
regulated through phosphorylation of specific serine or threonine residues (Karin and Smeal 
1992; Mumby and Walter 1993). To test whether protein phosphatases are involved in 
regulation of the ED-LI promoter DG75 cell transfected with LRS reporter constructs were 
treated with the PP1 and PP2A specific inhibitor okadaic acid (Holmes and Boland 1993). 
This showed a low but significant increase of LRS activity and this effect was dependent on 
an intact ATF/CRE. EBNA2 has previously been shown to associate with a protein of 31 kDa 
(Randahl et al. 1992), which is approximately the size of the catalytic subunit of PP1 and 
PP2A (Cohen 1989). Furthermore, several other transforming viruses encode transcriptional 
activators that have been shown to bind and inhibit protein phosphatases (Pallas et al. 1990; 
Yang et al. 1991; Kleinberger and Shenk 1993). This made us investigate whether EBNA2 
could interact with PP1 and PP2A. Cell extracts from the EBNA2 expressing lymphoblastoid 
cell line Cherry or the EBV negative B-cell line DG75 were fractionated by immunoaffinity 
chromatography with anti-EBNA2 antibodies as described previously (Dillner et al. 1988). 
Microcystin labeled with 125I was used for detection. Microcystin interacts specifically with 
the catalytic subunit of PP1 and PP2A (Holmes and Boland 1993). With this approach we 
could see that PP1/PP2A activity co-purified with EBNA2 from Cherry extracts. No 
PP1/PP2A activity was detected in the corresponding fractions from DG75 extracts. 
Furthermore, recombinant EBNA2 in fusion with the glutathione S-transferase (GST) protein 
could specifically interact with PP1/PP2A in DG75 cell extracts while GST alone could not. 
This recombinant EBNA2 could also inhibit a PP1 -like activity in nuclear extracts from DG75 
cells. The interaction and inhibition were restricted to amino acid 324-436 in the EBNA2 
protein, which overlaps with regions in EBNA2 known to be essential in both transformation 
of B-cells and promoter transactivation (Cohen et al. 1991; Sjöblom et al. 1995). This 
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suggests that this EBNA2 interaction with and inhibition of a PPl-like activity might play an 
important role in EBNA2's effect on LMP1 gene transcription, but could of course also be 
involved in other cellular processes where both EBNA2 and protein phosphatase activity are 
important. 
Paper II 
The next step in our investigation was to identify the factors binding to the identified 
regulatory elements in the proximal part of LRS. However, the first binding study using the 
electrophoretic mobility shift assay (EMSA) revealed that the specific mutation of the 
ATF/CRE site used in Paper I prevents the binding of factors both to the Sp site and the 
ATF/CRE site. To assess the relative contribution of the two binding sites to the promoter 
activity, new LRS reporter plasmids were created with specific mutations of the Sp and 
ATF/CRE motifs in pgLRS(-106)CAT and pgLRS(-634)CAT, respectively and co-transfected 
with EBNA2 in D G75 cells. The results showed that both sites are important for the EBNA2 
dependent transactivation of the LMP1 promoter. RNase protection assay (RPA) was 
performed to confirm that the observed transactivation of the ED-LI promoter was due to 
correct initiation. 
Factors in DG75 cells binding to the Sp and ATF/CRE sites were then characterised with 
EMSA. Five specific complexes were identified in DG75 cells. Similar binding patterns were 
obtained with both EBV-negative and EBV-postive B-cell extracts as well as with extracts 
from T-cells and epithelial cells. Two complexes were shown to be Sp related and three 
ATF/CRE related as determined with competition with probes containing either the consensus 
for Sp or ATF/CRE and LRS probes with either Sp or ATF/CRE mutated. To identify which 
members in the Sp and ATF/CREB transcription factor families that m ight be involved in the 
formation of the complexes, antibody super shift analysis were performed. One of the Sp 
related complexes was shifted by an anti-Spl antibody and two complexes with an anti-Sp3 
antibody. One of the Sp3-containing complexes was hidden behind the much stronger band 
corresponding to the Spl complex and therefore became evident only when the anti-Spl and 
anti-Sp3 antibodies were added simultaneously. The analysis of the three ATF/CRE related 
complexes revealed that they contained two different transcription factor heterodimers. Two 
complexes were shifted by both an anti-CREB and an anti-ATFl antibody. The third 
ATF/CRE related complex was removed by both an anti-ATF2 and an anti-c-Jun antibody 
and shifted by another anti-c-Jun antibody. 
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To assess the ability for the dif ferent transcription factors that bound Sp and ATF/CRE in 
LRS to transactivate the LMP1 promoter transient transfection experiments were performed. 
Expression vectors encoding the different transcription factors were co-transfected with 
pgLRS(-106)CAT with or without EBNA2. The Spl transcription factor induced a low level 
of activation in absence of EBNA2 but it did not add to the activity of the pgLRS(-106)CAT 
induced by EBNA2, although mutation of the Sp site largely abolished promoter activity. The 
Sp3 transcription factor has been shown to function as a repressor of Spl-mediated 
transcriptional activation (Hagen et al. 1994). This suggests that S pl can activate the LMP1 
promoter independently of EBNA2 and that this activity might be modulated by the Sp3 
transcription factor and that the integrity of the Sp site i s important for EBNA2 dependent 
activation of the LMP1 promoter. The ATF1 and CREB transcription factors could both 
separately and together activate the LMP1 promoter in the absence of EBNA2 and this effect 
was just as strong as the EBNA2 dependent activation of the LMP1 promoter. The effect was 
ATF/CRE dependent as shown by reduced or abolished activity when the ATF/CRE was 
mutated. No additional activation was detected when EBNA2 was co-transfected with ATF1, 
CREB. The ATF2 and c-Jun transcription factors, on the other hand, did not activate the 
LMP1 promoter in absence of EBNA2 neither alone nor together. Co-expression of either 
ATF2 or c-Jun together with EB NA2 showed only a weak increase of the promoter activity. 
However, co-expression of both ATF2 and c-Jun with EBNA2 gave a strong activation in a 
ATF/CRE dependent fashion. 
The EBNA2 dependent activation with ATF 2 and c-Jun was in l ine with the observation that 
in vitro translated EBNA2 abrogated the binding of in vitro translated heterodimeric c-Jun and 
ATF2 to the ATF/CRE in EMSA experiments. EBNA2 did not affect the respective 
homodimeric forms of ATF2 or c-Jun, suggesting that EBNA2 interacted with a 
heterodimeric ATF2/c-Jun complex. This notion gained further support by 
immunoprecipitation experiments. An EBNA2 expression vector was transfected together 
with expression vectors for c-Jun and ATF2 in DG75 cells. The transfected cells were 
selected with anti-CD2 antibodies. After lysis of the cells, the proteins were immuno-
precipitated with specific antibodies and visualised with immunoblot. The results showed that 
EBNA2 co-precipitated with both c-Jun and ATF2 when anti-c-Jun or anti-ATF2 antibodies 
were used. This suggests that the interaction of EBNA2 with ATF2 and c-Jun might b e a step 
in the transactivation of the LMP1 promoter. We have speculated (Paper I) that the ability of 
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EBNA2 to interact with and inhibit a factor with PPl-like activity might play an important 
role for the stimulatory effect of EBNA2 on LMP1 gene transcription. Since the identified 
LRS-ATF/CRE binding factors are regulated through phosphorylation and dephosphorylation 
we wanted to answer the question if EBNA2 could change the level of phosphorylation of 
these transcription factors. This experiment was done in D G75 cells transfected with EBNA2 
or a control vector after selection of transfected cells. Immunoblots were performed with 
specific antibodies against phosphorylated ATF2, c-Jun, CREB and ATF1. The assay showed 
no significant EBNA2-induced changes in the phosphorylation level of any of the tested 
transcription factors in this cell line. It should, however, be noted that the endogenous level of 
phosphorylation of ATF2 is high in DG75 cells. 
Paper III 
In the third paper we moved our focus towards histone acetylation and its possible 
involvement in LRS regulation. The reason was an investigation in our laboratory showing 
that elements in the proximal part of the LMP1 promoter were involved in silencing of 
transcription. Inhibition of histone deacetylase activity with Trichostatin A (TSA) in EBV 
positive but EBNA2 negative cell lines activated LMP1 protein expression (Sjöblom-Hallén 
et al. 1999). Furthermore, it became clear from the literature that several transcriptional 
regulators possess histone acetyltransferase or deacetylase activity or the ability to recruit 
these activities to promoters resulting in modulation of transcription. In o rder to study histone 
acetylation at the LMP1 promoter during EBNA2 activation, we used the ER/EB2-5 cell line 
and the chromatin immuno-precipitation (ChIP) assay. The lymphoblastoid cell line 
ER/EB2-5 is conditional for EBNA2 localisation to the nucleus, and the function of EBNA2 
is strictly dependent on oestrogen (figure 8). Withdrawal of oestrogen from the medium 
results in down regulation of LMP1 expression and cell cycle arrest. (Kempkes et al. 1995a). 
The ChIP assay (Braunstein et al. 1996) with specific antibodies directed against the 
acetylated forms of histone H3 and histone H4 in combination with a sensitive quantitative 
PCR allowed us to investigate the effects of EBNA2 and Trichostain A on histone acetylation 
at the LMP1. 
The ER/EB2-5 cells were treated with ß-estradiol to activate EBNA2 or with TSA to inhibit 
deacetylase activity and harvested during a time course of 24 hours. The subsequent ChIP 
assay showed a clear increase in acetylation level of histone H3 and H4 at the LMP1 promoter 
39 
already 30 minutes after either EBNA2 activation or TSA treatment. This increase was 
independent of de novo protein synthesis as determined by cyclohexamid treatment (CHX). 
RNase protection analysis (RPA) was performed to investigate if increased histone acetylation 
also resulted in transcriptional activation of the LMP1 ED-LI promoter. The experiment 
showed that EBNA2 but not TS A treatment activated transcription of the promoter in resting 
ER/EB2-5 cells in spite of the observed increase in his tone acetylation at the promoter. The 
results were also in contrast to those obtained previously with the EBV positive but EBNA2 
negative BL lines P3HR1 and Daudi, where TSA could induce LMP1 protein expression. 
ChlP assay and RPA an alysis of TSA treated P3HR1 cells verified the latter finding, where 
both increased histone acetylation at the promoter and induced transcription could be seen. 
Taken together, the results indicated that histone acetylation precedes transcription of the 
LMP1 gene in absence of de novo protein synthesis but additional events are also needed to 
activate the LMP1 transcription in resting ER/EB2-5 cells. This is in contrast to the situation 
in proliferating P3HR1 cells, where inhibition of histone deacetylation alone can induce 
activation. 
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Figure 8. The ER/EB2-5 cell line is established by infection of primary B-cells with the EBNA2-deficient 
P3HR1 virus strain (B) complemented by an EBNA2-oestrogen receptor fusion construct (A). The function of 
this ER/EBNA2 fusion protein is strictly dependent on oestrogen. Oestrogen withdrawal leads to inactivation of 
EBNA2 followed by down regulation of the LMP1 promoter and cell cycle arrest. Reproduced from (Kempkes 
et al. 1995c). The alternative nomenclature for the EBNA3-6 is used in the figure. See table 2. 
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To investigate possible common regulatory elements involved in histone acetylation we 
compared TS A and EBNA2 activation of the LMP1 promoter in a transient transfection assay. 
This was done in DG75 cells transfected with reporter plasmids containing 5'-end deleted 
LRS fragments together with EBNA2 expression vector or a control vector. TSA was added 
24 hours after transfection and cells were harvested 24 hours later. Both TSA and EBNA2 
could activate the promoter when the ATF/CRE was included in the reporter plasmid. A 
further increase in activity was detected up to -106 relative to the initiation site. The more 
distal elements in LRS p articipated only in an EBNA2 dependent fashion. This showed that 
TSA could up-regulate the LMP1 promoter in a reporter plasmid and that the proximal part of 
the promoter is sufficient for activation of the LMP1 promoter for both TSA and EBNA2 in 
proliferating B-cells. Two of the elements in the proximal part of the LMP1 promoter were 
considered as potential candidates for involvement in regulation of histone acetylation, the 
ATF/CRE-site described in paper I and II and an E-box element (Sjöblom-Hallén et al. 1999). 
Mutational analysis of these elements were therefore performed. Reporter constructs with 
either of these mutations, LRS-634(CREmut)luc or LRS-634(E-boxmut)luc were transfected 
into DG75 cells together with EBNA2 expression vector or a control vector. TSA was added 
24 hours after transfection and cells were harvested 24 hours later. This experiment showed 
that a mutation in the ATF/CRE decreased both the EBNA2 and the TSA induced activation 
almost to background level. Mutation in the E-box element did not relieve the repression of 
transcription from the LMP1 promoter, in the absence of EBNA2 or TSA, indicating that 
additional histone deacetylase activity associated to other regulatory elements are responsible 
for the repression of the promoter, e.g. the RPP-Jk response elements (Zhou et al. 2000). 
Since the ATF/CRE-site was vital in both EBNA2 and TSA induced activation of LMP1 
transcription in proliferating B-cells and as the previously identified factors binding to this 
element (paper II) are regulated through phosphorylation, we wanted to investigate the 
phosphorylation status of these factors in resting ER/EB2-5 cells and study them after TSA or 
ß-estradiol stimulation. We used phosphospecific antibodies directed against ATF2 and c-Jun. 
After ß-estradiol treatment and subsequent EBNA2 activation the immuno-blot clearly 
showed an increase in both phosphorylation and total amount o f ATF2 while c-Jun did not 
show any changes of neither phosphorylation nor total amount of protein. The increase in 
phosphorylation was evident after approximately 2 hours, which coincide with detectable 
amounts of transcripts from the ED-LI promoter as determined with RPA. However, TSA 
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treatment also led to a weak increase in ATF2 phosphorylation seen approximately after 2 
hours, but without detectable amounts of transcripts initiated from the ED-LI promoter. 
To further determine the role for phosphorylation of ATF2 in EBNA2 dependent activation of 
the LMP1 promoter we performed transient transfection experiments in DG75 cells. A 
reporter plasmid containing pgLRS(-106)CAT, was co-transfected together with expression 
vectors for c-Jun, ATF2 or ATF2mut(Ala69'71) in the presence or absence of EBNA2. This 
assay showed that mutation of the phosphorylated residues Thr69 and Thr71 in the ATF2 
protein decreased its ability to activate the LMP1 promoter. 
DISCUSSION 
To understand Epstein-Barr virus pathogenesis it is important to unravel the mechanisms 
involved in B-cell transformation and growth control during infection. The LMP1 is central in 
this understanding. Several of the viral latent gene products are involved in the regulation of 
the LMP1 gene, where EBNA2 plays the leading role. The cellular context is obviously 
important, since a number of cellular factors bind to the LRS and participate in LMP1 
regulation (figure 7). In this thesis data are presented that suggest that the proximal part of the 
promoter is important in both the EBNA2 dependent and independent regulation of the LMP1 
gene. 
Significance of the Sp element in LMP1 gene regulation 
The Sp factor-binding element is one of the most widely distributed promoter elements in 
cellular and viral genes. Several different Sp protein have been identified (Flagen et al. 1992; 
Kingsley and Winoto 1992). Mutational analysis and EMSA binding studies showed that an 
intact Sp element at position -33 in LRS is required for efficient transactivation of the LMP1 
promoter, both in absence and presence of EBNA2 (Paper II). The Sp transcription factor 
family has both activating (Spl, Sp2 and Sp4) and repressing (Sp3) members. Our data 
showed that at least Spl and Sp3 can bind to the -33 Sp site. Over-expression of the Spl 
factor had only a very small effect on promoter activity in absence of EBNA2 which did not 
increase in the presence of EBNA2. This was presumably due to the high abundance of 
endogenous Spl protein in DG75 cells. Transfection of Spl into the Spl-negative Schneider 
cells did not induce additional LRS-derived activity (data not shown). It seems reasonable to 
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propose that the Sp element is essential for LMP1 gene activity but the site does not seem to 
be responsible for the EBNA2 responsiveness of the proximal part of the promoter. The 
balance between Spl and Sp3 might be important for determining the final level of LMP1 
promoter activity. 
Significance of the ATF/CRE element in LMP1 gene regulation 
The ATF/CRE motif belongs to one of the major classes of regulatory elements that 
participate in transcriptional regulation induced by extracellular signals. Transcription 
regulators belonging to the ATF/CREB family bind to the ATF/CRE site as do members in 
the Fos/Jun transcription factor fam ily (Hai et al. 1989). The latter factors preferentially bind 
to AP-1 binding sites or TPA responsive elements (TRE) (Angel and Karin 1991) but the 
consensus sequence for ATF/CRE differs with only one nucleotide from that o f TRE. The 
ATF/CREB and Fos/Jun fam ilies constitute a superfamily where the different members can 
form cross-family heterodimers and thereby become able to bind to each o ther's recognition 
sites (Hai and Curran 1991). The factors activate transcription of target genes in response to a 
diverse array of stimuli, including peptide hormones and growth factors but are also utilised 
by viruses to induced modulation of transcription (Flint and Jones 1991; Sheng et al. 1991; 
Delmas et al. 1994; Mogensen and Paludan 2001). The factors are activated by a variety of 
protein kinases including protein kinase A (PKA), mitogen-activated protein kinases 
(MAPKs), stress activated protein kinases (SAPK) and Ca2+/calmodulin-dependent protein 
kinases (CaMKs). These kinases phosphorylate the transcription factors at particular residues 
and phosphorylation is necessary to mediate a response. 
We have established the importance of an ATF/CRE motif in the regulation of the LMP1 
promoter by both mutational and functional an alysis (Paper I-III). Mutations of the ATF/CRE 
decreased both EBNA2 dependent and independent LMP1 promoter activity in transient 
transfection experiments in DG75 cells. This was also observed after transfection of the 
ATF/CRE binding antagonist CREMß. This effect was dependent on an intact ATF/CRE 
sequence. The LMP1 promoter was activated by cAMP both in tran siently transfected cells 
and in EBV positive LCLs. The location of the ATF/CRE site at position -41 and the high 
turnover of the LMP1 gene product correlate well with properties of other cAMP regulated 
genes (Roesler et al. 1988). Studies on signalling transduction in the epithelial cell line HeLa 
have shown that the LMP1 promoter can be activated by the PKA pathway in the absence of 
EBNA2 (A. Jansson et ai, unpublished investigation), indicating that PKA is sufficient for 
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activation of the LMP1 gene in epithelial cells, ft is previously known that increase in cAMP 
levels results in growth retardation in some transformed B-cell lines (Friedman 1982). This 
was also seen in DG75 cells in our assays. Interestingly, LMP1 expression seemed to confer 
resistance to the inhibition of proliferation by cAMP. This might be relevant in vivo due to the 
importance of the cAMP signalling pathways in differentiation and survival of B-cells, where 
increased cAMP levels lead to apoptosis in resting B-cells as well as in germinal centre B-
cells (Knox et al. 1993; Newell et al. 1993). Possibly, EBV needs to respond to such apoptotic 
signals by up-regulation of the LMP1 gene and the ATF/CRE site would provide a direct link 
between cell signal and viral response. 
EMSA binding studies of the ATF/CRE site in LRS showed that a heterodimers consisting of 
CREB and ATF1 subunits could bind to the element (paper II). CREB and ATF1 are both 
regulated by PKA and PP1 or PP2A (Hagiwara et al. 1993; Wadzinski et al. 1993). However, 
over-expression of CREB and ATF1 showed that both factors induced LMP1 promoter 
activity in DG75 cells in the absence of EBNA2. Co-expression of EBNA2 gave no additional 
effect. This suggests that these factors are not responsible for the EBNA2 responsiveness. 
Instead, it is probable that they are involved in EBNA2 independent activation of LMP1 
expression in both B-cells and epithelial cells. Previous investigations have shown that 
activation of the protein kinase C (PKC) pathway by cross-linking of cell surface 
immunoglobulins (Rowe et al. 1992), treatment with the phorbol ester TPA or n-butyrate 
(Rowe et al. 1987; Contreras-Salazar et al. 1990) can induce LMP1 expression in BL-cell 
lines in the absence of EBNA2. The PKC pathway normally activates transcription through 
transcription factors binding to TRE sites but CREB and ATF1 binding to ATF/CRE can be 
regulated by PKC (Xie et al. 1993; Xie et al. 1996). This is compatible with the notion that 
activation of the PKC pathway might activate LMP1 expression via binding of the CREB and 
ATF1 transcription factors to ATF/CRE in LRS. We conclude that both the PKA and PKC 
signalling pathways are involved in LMP1 gene regulation and that at least PKA but possibly 
also PKC utilises the CREB and ATF1 transcription factors and the ATF/CRE site for 
activation. These reaction pathways seem to be EBNA2 independent under most 
circumstances. 
Our EMSA binding studies of the ATF/CRE also revealed that a heterodimer between ATF2 
and c-Jun could bind to the element (paper II). In contrast to the CREB and ATF1 factors, this 
heterodimeric factor complex did not induce LMP1 promoter activity in the absence of 
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EBNA2. However, in the presence of EBNA2, the heterodimeric complex induced a 
pronounced activating effect on the LMP1 promoter. Furthermore, EMSA and co-
immunoprecipitation experiments supported the notion that EBNA2 makes a direct contact 
with c-Jun and ATF2 as a heterodimer complex (Paper II). EBNA2 interacts with several 
other transcription regulatory factors that can bind to the LMP1 promoter. Notably, EBNA2 
presumably exists as a dimer or multimer (Grässer et al. 1991 ; Tsui and Schubach 1994). The 
interacting factors include the RBP-Jk (Ling et al. 1993a; Grossman et al. 1994; Henkel et al. 
1994; Waltzer et al. 1994; Zimber-Strobl et al. 1994), the Ets-related PU.l factor (Laux et al. 
1994a; Johannsen et al. 1995; Sjöblom et al. 1995a; Sjöblom et al. 1995b), and an unidentified 
member of the POU-domain protein family (Sjöblom et al. 1995a). These multiple 
interactions between DNA-binding transcription factors and EBNA2 are probably needed to 
form a stable multiprotein complex at the promoter. This give EBNA2 the opportunity to 
recruit additional co-factors required for transcriptional activation. The latter factors include 
the co-activators CBP, p300, PCAF (Jayachandra et al. 1999; Wang et al. 2000), members in 
the RNA polymerase II preinitiation complex (a et al. 1995; Tong et al. 1995b; Tong et al. 
1995c; Wu et al. 1996) and the chromatin remodelling machinery (Wu et al. 1996; Wu et al. 
2000). In conclusion, our data supports the idea that EBNA2 also utilises the ATF2 and c-Jun 
factors and the ATF/CRE site for the activation of the LMP1 promoter and that the EBNA2 
responsiveness of the promoter in part arises from this element. 
EBNA2 and protein phosphorylation in LMP1 gene regulation 
In a series of experiments the possible interaction between EBNA2 and protein phosphatase 1 
(PP1) or PP2A and ability of EBNA2 to inhibit the phosphatase activity in B-cells were 
investigated (Paper I). Several transforming viruses encode transcription factors that interact 
with protein phosphatases (Pallas et al. 1990; Yang et al. 1991; Kleinbürger and Shenk 1993; 
Sontag et al. 1993), showing that viruses have evolved strategies for affecting the response of 
the infected host cell by modulating the activity of cellular protein phosphatases. We found 
that EBNA2 bound to and inhibited the activity of a factor displaying a PP1 -like activity in 
the cells. The amino acid residues 324-436 in the EBNA2 protein were sufficient for both 
binding and inhibition of the PP1 -like activity. The enzymatic activity inhibited by EBNA2 
was also inhibited by the PP1 specific inhibitor-1 peptide. However, the 324-436 EBNA2 
fragment did not inhibit partially purified PP1 from rabbit skeletal muscle (data not shown). 
This indicates that a targeting factor is present in the DG75 nuclear extracts or that post-
translational modifications of the EBNA2 polypeptide are required. The amino acids in 
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EBNA2 responsible for the interaction and the inhibition of the PP1 -like activity partly 
overlap with d omains in EBNA2 important for B-cell transformation and transactivation of 
the Cp and LMP1 promoter (figure 5). The activation of LRS-derived CAT activity by 
okadaic acid demonstrates the involvement of PP1 or PP2A activity in the repression of the 
LMP1 promoter. Therefore, it is tempting to speculate that one of the functions of EBNA2 in 
the activation of LMP1 expression is to diminish the effect exerted by the protein 
phosphatases on a certain transcription factor. 
Transfection of EBNA2 in DG75 cells did not reveal any effects of EBNA2 on the 
phosphorylation status of CREB, ATF1, ATF2 or c-Jun (paper II). It should be noted that at 
least ATF2 was already highly phosphorylated also in the absence of EBNA2 in the cells. 
However, analysis of the phosphorylation status of these factors during EBNA2 activation of 
ER/EB2-5 cells (paper III) demonstrated a low level of phosphorylated ATF2 in resting 
ER/EB2-5 cells which increased significantly after EBNA2 induction. TSA treatment also led 
to a weak increase in ATF2 phosphorylation in ER/EB2-5 cells apparent after 2 hours. 
However, the TSA induced increase was only transient, phosphorylation of ATF2 decreased 
after 4 hours and was below the detection level after 8 hours (data not shown). A low level of 
phosphorylated ATF2 in the cells might possibly lead to a low activity of the ED-LI promoter 
and explain the absence of transcripts initiated from this promoter in ER7EB2-5 cells after 
TSA treatment. We have also analysed the phosphorylation level of ATF2 in P3HR1 cells. 
The level of phosphorylated ATF2 turned out to be high both in the untreated P3HR1 cells 
and cells incubated with TSA for 24 hours (data not shown). Furthermore, mutation of the 
phosphate-accepting amino acid residues Thr69 and Thr71 in ATF2 abolished the ability of 
the corresponding expression vector to induce LRS-derived CAT activity in transfected DG75 
cells. Taken together, our data strongly support the notion that phosphorylation of ATF2 is 
required for transcription of LMP1 in B-cells. This might be an effect mediated by EBNA2 
via inhibition of PP1, but further studies are necessary to confirm such a notion. We were not 
able to determine if the phosphorylation of ATF2 depended on de novo protein synthesis, 
since cyclohexamid (CHX) treatment itself increased ATF2 phosphorylation (data not shown) 
probably due to activation of the p38/MAPK pathway (Zinck et al. 1995). The fact that LMP1 
also can activate the p38/MAPK pathway and subsequently induce ATF2 phosphorylation 
(Eliopoulos et al. 1999b), indicates that an auto-regulatory loop might be involved in LMP1 
regulation. 
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It is also possible that the EBNA2 inhibition of PP1 instead influences other transcription 
factors at the LMP1 promoter (e.g. RNA pol. II CTD or the PU.l transcription factor) or other 
viral or cellular promoters involved in other functions, such as cell cycle regulation and 
growth control. It was recently reported that EBNA2 can induce p21WAFI expression by 
promoting p53 phosphorylation (Lin et al. 2000). Both PP1 and PP2A have been shown to 
dephosphorylate p53 and decrease p53 DNA-binding activity (Takenaka et al. 1995). Notably, 
a deletion in the EBNA2 region that interacts with PP1 could not activate the p21WAF1 
promoter (Lin et al. 2000). 
Histone acetylation and LMP1 gene regulation 
Repression of gene expression is accomplished by several different mechanisms, including 
covalent modifications like histone deacetylation, and non-covalent modifications of the 
nucleosome structure that leads to a more restricted chromatin structure. The repression must 
be removed in order to activate transcription. At least two different elements in LRS have 
been implicated in silencing of the LMP1 promoter through recruitment of histone 
deacetylase complexes. The RBP-Jk sites in the distal part of the promoter and an E-box motif 
(position -56 to -51) in the proximal part of the promoter. The repression mediated by 
RBP-JK on promoters is probably mediated by a co-repressor complex containing CIR, 
SMRT, Sin3A, SAP30 and the histone deacetylases HDAC1 and HDAC2 (Hsieh et al. 1999; 
Zhou et al. 2000). The connection between the E-box motif and silencing of the LMP1 
promoter has been investigated in our laboratory (Sjöblom-Hallén et al. 1999). Our 
experiments showed that a Max-Madl-Sin3A complex binds to the E-box site and probably 
recruits a co-repressor complex containing HDAC1 and HDAC2. Accordingly, inhibition of 
histone deacetylase activity with the specific inhibitor Trichostatin A (TSA) activated LMP1 
protein expression in the EBV positive cell lines P3HR1 and Daudi that do not express 
EBNA2 (Sjöblom-Hallén et al. 1999). However, TSA did not activate LMP1 expression in the 
Rael BL-line. The EBV genome in this cell line is known to be heavily methylated and 
treatment with the demethylating agent 5-azacytidine induced LMP1 expression (Masucci et 
al. 1989; Sjöblom-Hallén et al. 1999). Upregulation of LMP1 might to some extent be a 
secondary effect since 5-azacytidine also upregulated EBNA2 (Masucci et al. 1989). 
In paper III we investigated histone acetylation at the LMP1 promoter using the ER/EB2-5 
cell line which is conditional for EBNA2 expression (Kempkes et al. 1995a) (figure 8). An 
advantage of this conditional cell system is the possibility to obtain synchronised and resting 
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B-cells before the activation of EBNA2 is initiated. The activation leads to induction of 
EBNA2 responsive genes including the LMP1 promoter, generating a system that to some 
extent resembles a primary EBV infection. This system have been used in several 
investigations and has proved to be very useful to unravel details of the mechanisms involved 
in EBNA2 and LMP1 functions (Kempkes et al. 1995c; Jochner et al. 1996; Kempkes et al. 
1996; Kaiser et al. 1999; Gordadze et al. 2001; Spender et al. 2001). 
In our studies with the synchronised and resting ER/EB2-5 cells, estrogen-induced EBNA2 
activation or TSA treatment almost immediately increased acetylation of the H3 and H4 
histones at the LMP1 promoter. However, only EBNA2 was able to induce LMP1 
transcription. This was in contrast to the results obtained with proliferating P3HR1 cells, 
where TSA both increased histone acetylation at the LMP1 promoter and induced LMP1 
transcription. This shows that inhibition of histone deacetylation can substitute for EBNA2 
with regard to LMP1 expression in proliferating EBV transformed, B-cells not expressing 
EBNA2, but not in resting B-cells. Thus additional mechanisms for the repression of LMP1 
expression must exist in resting B-cells as compared with dividing cells. Resting cells have 
presumably a much more condensed chromatin structure. The fact that EBNA2 can bind to a 
subunit of the human Swi/Snf ATPas dependent chromatin remodelling complex suggests that 
EBNA2 might recruit this machinery to promoters in order to relieve repression (Wu et al. 
1996; Wu et al. 2000). Presumably, TSA can not activate this system, since TSA is a rather 
specific inhibitor of HDACs (Marks et al. 2000). Notably, P3HR1 cells are able to proliferate 
in the absence of EBNA2, partly due to the presence of a deregulated c-myc gene. It is known 
that TSA down-regulates and EBNA2 upregulates the normal wild type c-myc gene, which is 
the one present in ER/EB2-5 cells (Van Lint et al. 1996; Kaiser et al. 1999). These differences 
suggest that the proliferative phenotype of the cells is a prerequisite for the ability of TSA to 
activate the LMP1 gene. 
A deletion series of LRS to identify elements involved in TSA activation showed that full 
responsiveness was reached with a construct containing a short segment of the proximal part 
of the promoter. Mutational analysis of the regulatory elements in LRS showed that TSA 
activation required an intact ATF/CRE just like EBNA2. However, mutation of the E-box did 
not eliminate the requirement for EBNA2 or TSA. The absence of such an effect can be 
explained by the fact that additional histone deacetylase activity associated to other regulatory 
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elements is responsible for the repression of the promoter, such as the RBP-JK response 
element (Zhou et al. 2000)). 
All the transcription factors that can bind to the CRE/ATF element in LRS, interact with co-
activators such as CBP, p300 and PCAF and these interactions are required for activation of 
the promoter, reviewed in (Vo and Goodman 2001). Since CBP, p300, PCAF and ATF2 
possess intrinsic HAT activity and have been shown to interact directly or indirectly with 
EBNA2 (Paper II; Jayachandra et al. 1999; Wang et al. 2000), they could all be involved in 
the observed increase of histone acetylation at the LMP1 promoter. It has also been shown 
that over-expression of ATF2/c-Jun and p300 enhance the ability for EBNA2 to up-regulate 
LMP1 expression (Paper II; Wang et al. 2000). In the case of p300, this is probably 
accomplished by bridging effects from other transcription factors to the promoter, since the 
effect was not dependent on the HAT activity of p300 (Wang et al. 2000). This indicates that 
the histone acetylation at the LMP1 promoter must be achieved by some other transcription 
factor. The increased phosphorylation of ATF2 seen during activation of resting ER/EB2-5 
cells suggested that ATF2 could be one candidate for this. However, increased histone 
acetylation was seen before the observed increase of phosphorylated ATF2 in the ER/EB2-5 
cells. This indicates that at least the early phase of histone acetylation at the LMP1 promoter 
is performed by some other histone acetyltransferase. 
SWI/SNF ( RBP-J 
P300/CBP 
HAT 
TFIID(TFIII 
RNApol II 
PU-box 
Octamer 
RBP-JK 
E-box ATF/CRE 
Figure 9. Proposed model for EBNA2 activation of the LMP1 ED-LI promoter. EBNA2 makes direct contact 
with transcription factors bound to LRS (RBP-JK/SKIP, PU.L/POU protein and c-Jun/ATF). EBNA2 then 
recruits additional complexes (p300/CBP, Swi/Snf and GTFs) to remodel t he chromatin structure and to allow 
binding of the RNA polymerase II, which leads to activated transcription. EBNA2 might also influence the 
phosphorylation status of some of the factors involved through inhibition of PP1 (e.g. ATF2) to facilitate 
transcription. 
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Concluding remarks 
The proposed model for regulation of the LMP1 gene in B-cells is that at least two elements, 
the E-box and RBP-Jk binding sites, are involved in the silencing of the promoter through 
recruitment of histone deacetylase activity. However, additional mechanisms are also 
involved in the repression, since inhibition of histone deacetylase is not sufficient to activate 
transcription of LMP1 in resting B-cells and some BL-cell lines. These mechanisms probably 
include both a more condensed chromatin structure and DNA-methylation. 
Multiple elements in the LMP1 enhancer and promoter region have been implicated in the 
activation of the LMP1 gene and have been extensively investigated. However, our current 
understanding of their relative contribution in the different stages in EBV infection and in 
malignant disease is still incomplete. Our own results and those of other investigators suggest 
that at least three regions of LRS and the factors binding to them are needed for appropriate 
EBNA2 activation: the RBP-Jk binding site, the PU-box and octamer motif and the ATF/CRE 
region. EBNA2 probably needs to make direct contact with some or all of the factors binding 
to these elements to create a stable multiprotein complex at the promoter and to remove 
repressor complexes. EBNA2 also recruits other factor complexes needed for remodelling of 
the chromatin structure and transcription initiation (figure 9). 
The requirement for different regulatory factors both in EBNA2 dependent and independent 
activation of the LMP1 gene probably varies depending on cell cycle and differential stage 
but also the cellular context as a whole. The challenge for the future is to understand the 
combinatorial action of all these different factors and how they influence the expression of the 
LMP1 gene both in normal infection and in malignant disease. The current development of 
new techniques where many gene products, both at RNA and protein level, can be studied 
simultaneously might be the tool to unravel the intricate mechanisms involved. 
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